gral-2024063000016990312024Q212/31FalseP4Y25xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:puregral:tradingDay00016990312024-01-012024-06-3000016990312024-08-1100016990312024-06-3000016990312023-12-310001699031us-gaap:NonrelatedPartyMember2024-06-300001699031us-gaap:NonrelatedPartyMember2023-12-310001699031us-gaap:RelatedPartyMember2024-06-300001699031us-gaap:RelatedPartyMember2023-12-310001699031us-gaap:NonrelatedPartyMembergral:ScreeningRevenueMember2024-04-012024-06-300001699031us-gaap:NonrelatedPartyMembergral:ScreeningRevenueMember2023-04-012023-06-300001699031us-gaap:NonrelatedPartyMembergral:ScreeningRevenueMember2024-01-012024-06-300001699031us-gaap:NonrelatedPartyMembergral:ScreeningRevenueMember2023-01-012023-06-300001699031us-gaap:RelatedPartyMembergral:ScreeningRevenueMember2024-04-012024-06-300001699031us-gaap:RelatedPartyMembergral:ScreeningRevenueMember2023-04-012023-06-300001699031us-gaap:RelatedPartyMembergral:ScreeningRevenueMember2024-01-012024-06-300001699031us-gaap:RelatedPartyMembergral:ScreeningRevenueMember2023-01-012023-06-300001699031gral:DevelopmentalServicesRevenueMember2024-04-012024-06-300001699031gral:DevelopmentalServicesRevenueMember2023-04-012023-06-300001699031gral:DevelopmentalServicesRevenueMember2024-01-012024-06-300001699031gral:DevelopmentalServicesRevenueMember2023-01-012023-06-3000016990312024-04-012024-06-3000016990312023-04-012023-06-3000016990312023-01-012023-06-300001699031us-gaap:NonrelatedPartyMembergral:DevelopmentalServicesRevenueMember2024-04-012024-06-300001699031us-gaap:NonrelatedPartyMembergral:DevelopmentalServicesRevenueMember2023-04-012023-06-300001699031us-gaap:NonrelatedPartyMembergral:DevelopmentalServicesRevenueMember2024-01-012024-06-300001699031us-gaap:NonrelatedPartyMembergral:DevelopmentalServicesRevenueMember2023-01-012023-06-300001699031us-gaap:RelatedPartyMembergral:DevelopmentalServicesRevenueMember2024-04-012024-06-300001699031us-gaap:RelatedPartyMembergral:DevelopmentalServicesRevenueMember2023-04-012023-06-300001699031us-gaap:RelatedPartyMembergral:DevelopmentalServicesRevenueMember2024-01-012024-06-300001699031us-gaap:RelatedPartyMembergral:DevelopmentalServicesRevenueMember2023-01-012023-06-300001699031us-gaap:NonrelatedPartyMember2024-04-012024-06-300001699031us-gaap:NonrelatedPartyMember2023-04-012023-06-300001699031us-gaap:NonrelatedPartyMember2024-01-012024-06-300001699031us-gaap:NonrelatedPartyMember2023-01-012023-06-300001699031us-gaap:RelatedPartyMember2024-04-012024-06-300001699031us-gaap:RelatedPartyMember2023-04-012023-06-300001699031us-gaap:RelatedPartyMember2024-01-012024-06-300001699031us-gaap:RelatedPartyMember2023-01-012023-06-300001699031gral:MembersCapitalMember2023-12-310001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001699031us-gaap:RetainedEarningsMember2023-12-310001699031us-gaap:RetainedEarningsMember2024-01-012024-03-3100016990312024-01-012024-03-310001699031gral:MembersCapitalMember2024-01-012024-03-310001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001699031us-gaap:CommonStockMember2024-03-310001699031gral:MembersCapitalMember2024-03-310001699031us-gaap:AdditionalPaidInCapitalMember2024-03-310001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001699031us-gaap:RetainedEarningsMember2024-03-3100016990312024-03-310001699031us-gaap:RetainedEarningsMember2024-04-012024-06-300001699031gral:MembersCapitalMember2024-04-012024-06-300001699031us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001699031us-gaap:CommonStockMember2024-04-012024-06-300001699031us-gaap:CommonStockMember2024-06-300001699031gral:MembersCapitalMember2024-06-300001699031us-gaap:AdditionalPaidInCapitalMember2024-06-300001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001699031us-gaap:RetainedEarningsMember2024-06-300001699031gral:MembersCapitalMember2022-12-310001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001699031us-gaap:RetainedEarningsMember2022-12-3100016990312022-12-310001699031us-gaap:RetainedEarningsMember2023-01-012023-03-3100016990312023-01-012023-03-310001699031gral:MembersCapitalMember2023-01-012023-03-310001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001699031gral:MembersCapitalMember2023-04-020001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-020001699031us-gaap:RetainedEarningsMember2023-04-0200016990312023-04-020001699031us-gaap:RetainedEarningsMember2023-04-032023-07-0200016990312023-04-032023-07-020001699031gral:MembersCapitalMember2023-04-032023-07-020001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-032023-07-020001699031gral:MembersCapitalMember2023-07-020001699031us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-020001699031us-gaap:RetainedEarningsMember2023-07-0200016990312023-07-0200016990312023-06-300001699031gral:SDGOpsLLCMembergral:IlluminaInc.Member2021-08-192024-06-230001699031gral:IlluminaInc.Member2024-06-240001699031gral:GrailInc.Membergral:IlluminaInc.Member2024-06-240001699031gral:IlluminaInc.Member2024-06-242024-06-240001699031gral:IlluminaInc.Member2024-06-240001699031us-gaap:DomesticCountryMember2023-12-310001699031us-gaap:StateAndLocalJurisdictionMember2023-12-310001699031gral:IlluminaInc.Member2024-06-230001699031us-gaap:MoneyMarketFundsMember2024-06-300001699031us-gaap:MoneyMarketFundsMember2023-12-310001699031gral:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001699031gral:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-06-300001699031gral:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-06-300001699031gral:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-04-012024-06-300001699031gral:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-06-300001699031us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2024-04-012024-06-300001699031us-gaap:DevelopedTechnologyRightsMember2023-12-310001699031us-gaap:DevelopedTechnologyRightsMember2024-06-300001699031us-gaap:TradeNamesMember2023-12-310001699031us-gaap:TradeNamesMember2024-06-300001699031us-gaap:InProcessResearchAndDevelopmentMember2024-06-300001699031us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001699031gral:IlluminaInc.Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:InProcessResearchAndDevelopmentMember2024-04-012024-06-300001699031gral:IlluminaInc.Memberus-gaap:InProcessResearchAndDevelopmentMember2024-04-012024-06-300001699031us-gaap:MeasurementInputDiscountRateMemberus-gaap:InProcessResearchAndDevelopmentMember2024-04-012024-06-300001699031us-gaap:InProcessResearchAndDevelopmentMember2024-04-012024-06-300001699031gral:CostOfScreeningRevenueMember2024-04-012024-06-300001699031gral:CostOfScreeningRevenueMember2023-04-012023-06-300001699031gral:CostOfScreeningRevenueMember2024-01-012024-06-300001699031gral:CostOfScreeningRevenueMember2023-01-012023-06-300001699031gral:CostOfDevelopmentServicesRevenueMember2024-04-012024-06-300001699031gral:CostOfDevelopmentServicesRevenueMember2023-04-012023-06-300001699031gral:CostOfDevelopmentServicesRevenueMember2024-01-012024-06-300001699031gral:CostOfDevelopmentServicesRevenueMember2023-01-012023-06-300001699031us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001699031us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001699031us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001699031us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001699031us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-300001699031us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-300001699031us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-300001699031us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-300001699031us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001699031us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001699031us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001699031us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001699031gral:TheGRAILInc.2024IncentiveAwardPlanMember2024-05-310001699031gral:TheGRAILInc.2024IncentiveAwardPlanMember2024-06-300001699031us-gaap:RestrictedStockUnitsRSUMember2023-12-310001699031us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001699031us-gaap:RestrictedStockUnitsRSUMember2024-06-300001699031us-gaap:EmployeeStockMembergral:TheGRAILInc.2024EmployeeStockPurchasePlanMember2024-05-310001699031us-gaap:EmployeeStockMembergral:TheGRAILInc.2024EmployeeStockPurchasePlanMember2024-01-012024-06-300001699031gral:TransitionIncentiveAwardMembergral:A2024TransitionIncentiveAwardPlanMember2024-04-012024-06-300001699031gral:TransitionIncentiveAwardMembergral:A2024TransitionIncentiveAwardPlanMember2024-01-012024-06-300001699031gral:TransitionIncentiveAwardMembergral:A2024TransitionIncentiveAwardPlanMember2024-06-300001699031gral:TransitionIncentiveAwardMembergral:A2024TransitionIncentiveAwardPlanMember2024-06-282024-06-280001699031us-gaap:RestrictedStockUnitsRSUMembergral:A2024TransitionIncentiveAwardPlanMember2024-06-280001699031gral:A2021CashBasedEquityAwardsProgramMember2024-01-012024-06-300001699031gral:A2021CashBasedEquityAwardsProgramMember2024-06-240001699031gral:A2021CashBasedEquityAwardsProgramMember2024-06-282024-06-280001699031us-gaap:RestrictedStockUnitsRSUMembergral:A2021CashBasedEquityAwardsProgramMember2024-06-280001699031gral:A2021CashBasedEquityAwardsProgramMember2023-12-310001699031gral:A2021CashBasedEquityAwardsProgramMember2024-01-012024-06-280001699031gral:A2021CashBasedEquityAwardsProgramMember2024-06-2800016990312024-06-292024-06-300001699031us-gaap:PerformanceSharesMembergral:FormerEmployeeMember2024-06-300001699031gral:FormerEmployeeMemberus-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-06-300001699031gral:FormerEmployeeMemberus-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-06-300001699031gral:FormerEmployeeMemberus-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-06-300001699031gral:FormerEmployeeMemberus-gaap:PerformanceSharesMembergral:ShareBasedPaymentArrangementTrancheFourMember2024-01-012024-06-300001699031us-gaap:EmployeeStockOptionMember2024-06-300001699031us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001699031us-gaap:EmployeeStockOptionMember2023-12-310001699031us-gaap:RelatedPartyMembergral:IlluminaInc.Member2024-06-300001699031us-gaap:RelatedPartyMembergral:IlluminaInc.Member2023-12-310001699031gral:CostOfScreeningRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2024-04-012024-06-300001699031gral:CostOfScreeningRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2023-04-012023-06-300001699031gral:CostOfScreeningRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2024-01-012024-06-300001699031gral:CostOfScreeningRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2023-01-012023-06-300001699031gral:CostOfDevelopmentServicesRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2024-04-012024-06-300001699031gral:CostOfDevelopmentServicesRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2023-04-012023-06-300001699031gral:CostOfDevelopmentServicesRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2024-01-012024-06-300001699031gral:CostOfDevelopmentServicesRevenueMemberus-gaap:RelatedPartyMembergral:IlluminaInc.Member2023-01-012023-06-300001699031us-gaap:RelatedPartyMembergral:IlluminaInc.Member2024-04-012024-06-300001699031us-gaap:RelatedPartyMembergral:IlluminaInc.Member2023-04-012023-06-300001699031us-gaap:RelatedPartyMembergral:IlluminaInc.Member2024-01-012024-06-300001699031us-gaap:RelatedPartyMembergral:IlluminaInc.Member2023-01-012023-06-300001699031srt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2024-06-300001699031srt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2023-12-310001699031gral:CostOfScreeningRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2024-04-012024-06-300001699031gral:CostOfScreeningRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2023-04-012023-06-300001699031gral:CostOfScreeningRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2024-01-012024-06-300001699031gral:CostOfScreeningRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2023-01-012023-06-300001699031gral:CostOfDevelopmentServicesRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2024-04-012024-06-300001699031gral:CostOfDevelopmentServicesRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2023-04-012023-06-300001699031gral:CostOfDevelopmentServicesRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2024-01-012024-06-300001699031gral:CostOfDevelopmentServicesRevenueMembersrt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2023-01-012023-06-300001699031srt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2024-04-012024-06-300001699031srt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2023-04-012023-06-300001699031srt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2024-01-012024-06-300001699031srt:ChiefExecutiveOfficerMembergral:TwistBioscienceMember2023-01-012023-06-3000016990312024-06-230001699031gral:TwentyTwentyFourRestructuringPlanMemberus-gaap:SubsequentEventMember2024-08-090001699031gral:TwentyTwentyFourRestructuringPlanMemberus-gaap:SubsequentEventMember2024-08-092024-08-090001699031gral:TwentyTwentyFourRestructuringPlanMemberus-gaap:SubsequentEventMembersrt:MinimumMember2024-08-090001699031gral:TwentyTwentyFourRestructuringPlanMemberus-gaap:SubsequentEventMembersrt:MaximumMember2024-08-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM 10-Q
___________________________________________
(Mark One)
| | | | | |
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2024
OR
| | | | | |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 001-42045
___________________________________________
GRAIL, Inc.
(Exact name of registrant as specified in its charter)
___________________________________________
| | | | | |
Delaware | 86-3673636 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
1525 O’Brien Drive Menlo Park, California | 94025 |
(Address of Principal Executive Offices) | (Zip Code) |
(833) 694-2553
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common stock, par value $0.001 per share | GRAL | The Nasdaq Stock Market LLC |
| | |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes o No x
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | |
Large accelerated filer | o | | Accelerated filer | o |
| | | | |
Non-accelerated filer | x | | Smaller reporting company | o |
| | | | |
| | | Emerging growth company | x |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes o No ☒
As of August 11, 2024, the registrant had 31,049,148 shares of common stock, par value $0.001 per share, outstanding.
| | | | | |
| Page |
Cautionary Note Regarding Forward-Looking Statements | |
Summary of Material Risks Associated with Our Business | |
| |
| |
Condensed Consolidated Balance Sheets | |
Condensed Consolidated Statements of Operations | |
Condensed Consolidated Statements of Comprehensive Loss | |
Condensed Consolidated Statements of Equity | |
Condensed Consolidated Statements of Cash Flows | |
Notes to Condensed Consolidated Statements | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would,” or “will,” the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations and projections of our future financial performance, future tests or products, technology, clinical studies, regulatory compliance, potential market opportunity, anticipated growth strategies, restructuring costs, sufficiency of cash on hand to finance our business, cost savings, budgets and strategies, restructuring and stock-based compensation costs, impact of the restructuring on our operations and anticipated trends in our business.
These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors discussed under the section entitled “Risk Factors.” You should specifically consider the numerous risks described under the section entitled “Risk Factors.” Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
Summary of Material Risks Associated with Our Business
The principal risks and uncertainties affecting our business include the following:
•We operate in a rapidly evolving field and have a limited operating history, which make it difficult to evaluate our current business and predict our future performance.
•We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the coming years.
•Our products or future products may not perform as expected, and the results of our clinical studies may not support the launch or use of our products or future products and may not comply with the requirements, or be replicated in later studies or in the post-market or real-world setting.
•The clinical study process is lengthy and expensive with uncertain outcomes. We have encountered delays and may encounter future delays in, or unexpected data from, our clinical studies, and may therefore be unable to complete our clinical studies on the timelines we expect, if at all.
•A substantial majority of our revenue is generated from sales of Galleri and we are highly dependent on it for our success.
•If our products do not receive adequate coverage and reimbursement, if at all, from third-party payors, our ability to expand access to our products beyond our existing sales channels will be limited and our overall commercial success will be limited.
•Our commercial products may fail to achieve the degree of market acceptance necessary for commercial success.
•We may not be able to generate sufficient revenue to offset our ongoing operating expenses and achieve and maintain profitability, and it may be difficult for us to offset the costs of our royalties, including the high single-digit royalty that we will be required to pay to Illumina in perpetuity or our royalties payable to the Chinese University of Hong Kong.
•We may be unable to develop and commercialize new products, including enhanced versions of current products.
•If similar third-party products are developed and do not perform as intended or cause harm or injury to patients, the market for our products could be impaired.
•If we fail to obtain additional financing, we may be unable to expand our commercialization efforts with respect to Galleri and any other products that we successfully develop and commercialize, or to develop additional products.
•If our products result in direct or indirect participant or patient harm or injury, we could be subject to significant reputational and liability risks
•We rely on Illumina as a sole supplier for our next-generation sequencers and associated reagents, Madison Industries (“Madison”) (who acquired our blood collection tube manufacturer, Streck, in 2023) as a sole supplier of our blood collection tubes, and Twist Bioscience Corporation (“Twist”) as a sole supplier of our DNA panels. Additionally, we rely on a limited number of suppliers for some of our laboratory instruments and reagents, and we may not be able to immediately find replacements if necessary.
•We have launched Galleri as a laboratory developed test (“LDT”) in the United States. The FDA recently finalized a regulation pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming.
•The regulatory clearance, approval, or certification processes of the FDA and comparable foreign regulatory authorities or notified bodies are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable regulatory approvals, clearances, or certifications, or if such approvals, clearances, or certifications are significantly delayed, our business will be substantially harmed.
•Our operations and business are materially dependent on various third parties, including information technology, sample collection, processing, transfer facilities, and other patient-facing service providers, any of which could experience disruption, failure, or interruption.
•If we are unable to scale our operations to support demand for our products, our business could suffer.
•Our multi-cancer detection tests are a new approach to cancer screening, and present novel and complex issues for FDA review. Because the FDA has never cleared or approved a multi-cancer detection test, it is difficult to predict what information we will need to submit to obtain approval of a PMA from the FDA for a proposed intended use, or if we will be able to obtain such approval on a timely basis or at all.
•If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection we obtain is not sufficiently broad, third parties could in the future develop and commercialize technology and tests similar or identical to ours, and our ability to successfully commercialize our products may be impaired.
•If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
•We could have an indemnification obligation to Illumina if the Distribution were determined not to qualify for non-recognition treatment for U.S. federal tax purposes.
•We have agreed to numerous restrictions to preserve the non-recognition treatment of the Spin-Off, which may reduce our strategic and operating flexibility.
•An active trading market for our common stock may not be sustained after the Spin-Off. Following the Spin-Off our stock price may fluctuate significantly.
•If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.
•Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or our products.
•We are an emerging growth company and the information we provide shareholders may be different from information provided by other public companies, which may result in a less active trading market for our common stock and higher volatility in our stock price.
•Substantial sales of our common stock may occur in connection with the Spin-Off, including the disposition by Illumina of the shares of our common stock that it retains after the Spin-Off, which could cause our stock price to decline.
The summary risk factors described above should be read together with the text of the full risk factors below in “Risk Factors” and the other information set forth in this Form 10-Q, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future growth prospects.
Part I - Financial Information
Item 1. Financial Statements
GRAIL, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS | | | | | | | | | | | |
(in thousands, except share and per share data) | June 30, 2024 | | December 31, 2023 |
Assets | (unaudited) | | |
Current assets: | | | |
Cash and cash equivalents. | $ | 958,845 | | | $ | 97,287 | |
Accounts receivable, net | 13,374 | | | 16,862 | |
Accounts receivable, net — related parties | 32 | | | 80 | |
Supplies | 18,196 | | | 14,788 | |
Supplies — related parties | 7,310 | | | 6,907 | |
Prepaid expenses and other current assets | 20,866 | | | 20,100 | |
Prepaid expenses and other current assets — related parties | 59 | | | 41 | |
Total current assets | 1,018,682 | | | 156,065 | |
Property and equipment, net | 74,984 | | | 81,355 | |
Property and equipment, net — related parties | 3,021 | | | 3,640 | |
Operating lease right-of-use assets | 74,503 | | | 84,386 | |
Restricted cash | 3,918 | | | 4,225 | |
Intangible assets, net | 2,086,056 | | | 2,687,223 | |
Goodwill | — | | | 888,936 | |
Other non-current assets | 8,476 | | | 7,984 | |
Total assets | $ | 3,269,640 | | | $ | 3,913,814 | |
| | | |
Liabilities and member’s/stockholders’ equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 16,247 | | | $ | 18,845 | |
Accounts payable — related parties | — | | | 828 | |
Accrued liabilities | 56,573 | | | 73,711 | |
Accrued liabilities — related parties | — | | | 95 | |
Incentive plan liabilities | — | | | 54,513 | |
Operating lease liabilities, current portion | 13,945 | | | 14,809 | |
Other current liabilities | 1,413 | | | 809 | |
Total current liabilities | 88,178 | | | 163,610 | |
Operating lease liabilities, net of current portion | 62,165 | | | 69,598 | |
Deferred tax liability, net | 422,163 | | | 32,921 | |
Other non-current liabilities | 2,007 | | | 1,498 | |
Total liabilities | 574,513 | | | 267,627 | |
| | | |
Preferred stock, par value of $0.001 per share; 50,000,000 shares authorized, no shares issued and outstanding as of June 30, 2024 and December 31, 2023 | — | | | — | |
Common stock $0.001 par value per share, 1,500,000,000 shares authorized, 31,049,148 shares issued and outstanding as of June 30, 2024, no shares authorized, issued and outstanding as of December 31, 2023 | 31 | | | — | |
Additional paid-in capital | 12,274,286 | | | — | |
Member’s equity | — | | | 11,421,446 | |
Accumulated other comprehensive income | 1,386 | | | 1,066 | |
Accumulated deficit | (9,580,576) | | | (7,776,325) | |
Total stockholders’/member’s equity | 2,695,127 | | | 3,646,187 | |
Total liabilities and stockholders’/member's equity | $ | 3,269,640 | | | $ | 3,913,814 | |
See accompanying notes to condensed consolidated financial statements.
GRAIL, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended |
(in thousands, except per share data) | June 30, 2024 | | July 2, 2023 | | June 30, 2024 | | July 2, 2023 |
Revenue: | | | | | | | |
Screening revenue | $ | 28,055 | | | $ | 19,863 | | | $ | 51,465 | | | $ | 35,183 | |
Screening revenue — related parties | 108 | | | 164 | | | 237 | | | 416 | |
Development services revenue | 3,807 | | | 2,387 | | | 6,989 | | | 6,458 | |
Total revenue | 31,970 | | | 22,414 | | | 58,691 | | | 42,057 | |
Costs and operating expenses: | | | | | | | |
Cost of screening revenue (exclusive of amortization of intangible assets). | 12,010 | | | 8,912 | | | 23,000 | | | 17,758 | |
Cost of screening revenue — related parties | 3,779 | | | 2,213 | | | 6,511 | | | 3,792 | |
Cost of development services revenue | 543 | | | 2,059 | | | 1,934 | | | 3,395 | |
Cost of development services revenue — related parties | 78 | | | 36 | | | 123 | | | 60 | |
Cost of revenue — amortization of intangible assets | 33,472 | | | 33,472 | | | 66,944 | | | 66,944 | |
Research and development | 88,727 | | | 82,311 | | | 185,117 | | | 162,832 | |
Research and development — related parties | 5,469 | | | 6,399 | | | 10,704 | | | 11,751 | |
Sales and marketing | 40,989 | | | 40,737 | | | 87,808 | | | 86,572 | |
General and administrative | 67,206 | | | 50,590 | | | 124,224 | | | 97,248 | |
General and administrative — related parties | 52 | | | 52 | | | 103 | | | 103 | |
Goodwill and intangible impairment | 1,420,936 | | | — | | | 1,420,936 | | | — | |
Total costs and operating expenses | 1,673,261 | | | 226,781 | | | 1,927,404 | | | 450,455 | |
Loss from operations | (1,641,291) | | | (204,367) | | | (1,868,713) | | | (408,398) | |
Other income (expense): | | | | | | | |
Interest income | 2,805 | | | 1,847 | | | 5,706 | | | 4,074 | |
Other income (expense), net | 5 | | | (320) | | | 47 | | | (225) | |
Total other income (expense), net | 2,810 | | | 1,527 | | | 5,753 | | | 3,849 | |
Loss before income taxes | (1,638,481) | | | (202,840) | | | (1,862,960) | | | (404,549) | |
Benefit from income taxes | 53,144 | | | 9,796 | | | 58,709 | | | 17,839 | |
Net loss | $ | (1,585,337) | | | $ | (193,044) | | | $ | (1,804,251) | | | $ | (386,710) | |
Net loss per share — basic and diluted | $ | (51.06) | | | $ | (6.22) | | | $ | (58.11) | | | $ | (12.45) | |
Weighted-average number of shares used in per share calculation — basic and diluted | 31,049,148 | | | 31,049,148 | | | 31,049,148 | | | 31,049,148 | |
See accompanying notes to condensed consolidated financial statements.
GRAIL, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended | | Six Months Ended |
(in thousands) | June 30, 2024 | | July 2, 2023 | | June 30, 2024 | | July 2, 2023 |
Net loss | $ | (1,585,337) | | | $ | (193,044) | | | $ | (1,804,251) | | | $ | (386,710) | |
Other comprehensive income: | | | | | | | |
| | | | | | | |
Foreign currency translation adjustment | 372 | | | 96 | | | 320 | | | 37 | |
Comprehensive loss | $ | (1,584,965) | | | $ | (192,948) | | | $ | (1,803,931) | | | $ | (386,673) | |
See accompanying notes to condensed consolidated financial statements.
GRAIL, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | | | | | | | | | |
(in thousands) | Shares | | Amount | | Member’s Equity | | Additional Paid in Capital | | Accumulated Other Comprehensive Income | | Accumulated Deficit | | Total stockholders’/member’s equity |
Balance as of December 31, 2023 | — | | | $ | — | | | 11,421,446 | | | $ | — | | | $ | 1,066 | | | $ | (7,776,325) | | | $ | 3,646,187 | |
Net loss | — | | | — | | | — | | | — | | | — | | | (218,914) | | | (218,914) | |
Stock-based compensation expense | — | | | — | | | 170 | | | — | | | — | | | — | | | 170 | |
Other comprehensive loss | — | | | — | | | — | | | — | | | (52) | | | — | | | (52) | |
Contribution from member, net | — | | | — | | | 312,000 | | | — | | | — | | | — | | | 312,000 | |
Balance as of March 31, 2024 | — | | | $ | — | | | $ | 11,733,616 | | | $ | — | | | $ | 1,014 | | | $ | (7,995,239) | | | $ | 3,739,391 | |
Net loss | — | | | — | | | — | | | — | | | — | | | (1,585,337) | | | (1,585,337) | |
Stock-based compensation expense | — | | | — | | | 156 | | | 640 | | | — | | | — | | | 796 | |
Other comprehensive income | — | | | — | | | — | | | — | | | 372 | | | — | | | 372 | |
| | | | | | | | | | | | | |
Recognition of deferred tax liability in connection with the Spin-Off* | — | | | — | | | (447,190) | | | — | | | — | | | — | | | (447,190) | |
Reclassification of incentive plan liabilities to additional paid-in capital | — | | | — | | | — | | | 54,795 | | | — | | | — | | | 54,795 | |
Disposal funding received in connection with the Spin-Off* | — | | | — | | | 932,300 | | | | | — | | | — | | | 932,300 | |
Issuance of common stock in connection with the Spin-Off and reclassification of contribution from member, net* | 31,049,148 | | | 31 | | | (12,218,882) | | | 12,218,851 | | | — | | | — | | | — | |
Balance as of June 30, 2024 | 31,049,148 | | | $ | 31 | | | $ | — | | | $ | 12,274,286 | | | $ | 1,386 | | | $ | (9,580,576) | | | $ | 2,695,127 | |
See accompanying notes to condensed consolidated financial statements.
___________
*See Note 1 — Organization And Description Of Business for more information on the Spin-Off.
GRAIL, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | | | | | | | | | |
(in thousands) | Shares | | Amount | | Member’s Equity | | Additional Paid in Capital | | Accumulated Other Comprehensive Income | | Accumulated Deficit | | Total Equity |
Balance as of January 1, 2023 | — | | | $ | — | | | $ | 10,955,907 | | | $ | — | | | $ | 894 | | | $ | (6,310,640) | | | $ | 4,646,161 | |
Net loss | — | | | — | | | — | | | — | | | — | | | (193,666) | | | (193,666) | |
Stock-based compensation expense | — | | | — | | | 799 | | | — | | | — | | | — | | | 799 | |
Other comprehensive loss | — | | | — | | | — | | | — | | | (59) | | | — | | | (59) | |
Contribution from member, net | — | | | — | | | 108,870 | | | — | | | — | | | — | | | 108,870 | |
Balance as of April 2, 2023 | — | | | $ | — | | | $ | 11,065,576 | | | $ | — | | | $ | 835 | | | $ | (6,504,306) | | | $ | 4,562,105 | |
Net loss | — | | | — | | | — | | | — | | | — | | | (193,045) | | | (193,045) | |
Stock-based compensation expense | — | | | — | | | 711 | | | — | | | — | | | — | | | 711 | |
Other comprehensive loss | — | | | — | | | — | | | — | | | 96 | | | — | | | 96 | |
Contribution from member, net | — | | | — | | | 194,905 | | | — | | | — | | | — | | | 194,905 | |
Balance at July 2, 2023 | — | | | $ | — | | | $ | 11,261,192 | | | $ | — | | | $ | 931 | | | $ | (6,697,351) | | | $ | 4,564,772 | |
See accompanying notes to condensed consolidated financial statements.
GRAIL, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(unaudited)
| | | | | | | | | | | |
| Six Months Ended |
(in thousands) | June 30, 2024 | | July 2, 2023 |
Cash flows from operating activities | | | |
Net loss | $ | (1,804,251) | | | $ | (386,710) | |
Adjustments to reconcile net loss to net cash used by operating activities: | | | |
Amortization of intangibles assets | 69,167 | | | 69,167 | |
Depreciation | 10,218 | | | 9,802 | |
Stock-based compensation expense | 55,053 | | | 47,064 | |
Cash payment for equity awards | (53,807) | | | (24,667) | |
Deferred income taxes | (57,949) | | | (16,069) | |
| | | |
Goodwill and intangible impairment | 1,420,936 | | | — | |
Other | 361 | | | (172) | |
Changes in operating assets and liabilities: | | | |
Accounts receivable | 3,488 | | | 4,273 | |
Accounts receivable — related parties | 48 | | | 164 | |
Supplies | (3,408) | | | (1,412) | |
Supplies — related parties | (403) | | | (1,498) | |
Operating lease right-of-use assets and liabilities, net | 1,586 | | | 4,306 | |
Prepaid expenses and other assets | (2,509) | | | 314 | |
Prepaid expenses and other current assets — related parties | (18) | | | 40 | |
Accounts payable | (2,486) | | | (3,822) | |
Accounts payable — related parties | (828) | | | (1,561) | |
Accrued and other liabilities | (14,188) | | | (8,501) | |
Accrued and other liabilities — related parties | (95) | | | (109) | |
Net cash used by operating activities | (379,085) | | | (309,391) | |
| | | |
Cash flows from investing activities | | | |
Purchases of property and equipment | (3,934) | | | (4,358) | |
Purchases of property and equipment — related parties | — | | | (1,565) | |
| | | |
| | | |
| | | |
Net cash used by investing activities | (3,934) | | | (5,923) | |
Cash flows from financing activities | | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Cash funding received from Illumina | 1,244,300 | | | 304,000 | |
| | | |
Taxes paid related to net share settlement of equity awards | — | | | (225) | |
Net cash provided by financing activities | 1,244,300 | | | 303,775 | |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (30) | | | 257 | |
Net increase (decrease) in cash, cash equivalents, and restricted cash | 861,251 | | | (11,282) | |
Cash, cash equivalents and restricted cash — beginning of period | 101,512 | | | 246,128 | |
Cash, cash equivalents and restricted cash — end of period | $ | 962,763 | | | $ | 234,846 | |
Represented by: | | | |
Cash and cash equivalents | $ | 958,845 | | | $ | 230,621 | |
Restricted cash | 3,918 | | | 4,225 | |
Total | $ | 962,763 | | | $ | 234,846 | |
Supplemental cash flow information: | | | |
| | | |
Property and equipment included in accounts payable and accrued liabilities | (628) | | | (1,135) | |
Operating cash flows from operating leases, net | (10,043) | | | (9,117) | |
See accompanying notes to condensed consolidated financial statements.
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS
GRAIL, Inc. (“GRAIL” or the “Company”), headquartered in Menlo Park, California, is an innovative commercial-stage healthcare company focused on saving lives and shifting the paradigm of early cancer detection. The Company’s Galleri blood test is a commercially available screening test for early detection of multiple types of cancer.
GRAIL was previously acquired by Illumina, Inc. (”Illumina”) in August 2021, at which point it became a 100% owned subsidiary of Illumina, and held separate as a part of binding hold separate commitments implemented pursuant to orders issued by the European Commission. See Note 9 — Legal And Regulatory Proceedings for additional details. GRAIL separated from Illumina on June 24, 2024, as described below. GRAIL was a limited liability company (“LLC”) from August 19, 2021 to June 21, 2024 when it was converted into a corporation (the “Conversion”) in anticipation of such separation.
Separation from Illumina
On June 24, 2024, (the “Distribution Date”), Illumina completed the previously announced spin-off of GRAIL (the “Spin-Off”). The Spin-Off was completed through a distribution of 85.5% of the Company’s outstanding common stock to the holders of record of Illumina’s common stock as of the close of business on June 13, 2024 (the “Distribution”), which resulted in the distribution of 31.0 million shares of common stock. As a result of the Distribution, the Company became an independent public entity. Illumina’s ownership of GRAIL reduced to 14.5% after the Spin-Off. GRAIL’s common stock is listed under the ticker symbol “GRAL” on the NASDAQ Stock Exchange. Unless the context otherwise requires, references to the Company or GRAIL, refer to (i) GRAIL, LLC prior to the Conversion and (ii) GRAIL, Inc. and its subsidiaries following the Conversion.
In connection with the Spin-Off, the Company entered into or adopted agreements that provide a framework for the relationship between the Company and Illumina, including, but not limited to the following:
•Separation and Distribution Agreement — governed the terms and conditions of the Spin-Off and sets forth aspects of the Company’s and Illumina’s relationship following the Spin-Off. See Note 9 — Legal And Regulatory Proceedings for more information regarding the contingencies related to this agreement.
•Tax Matters Agreement — governs the respective rights, responsibilities and obligations of Illumina and the Company after the Spin-Off with respect to all tax matters and includes restrictions to preserve the tax-free status of the Distribution. See Note 8 — Taxes for more information regarding income taxes and Note 9 — Legal And Regulatory Proceedings regarding the contingencies related to this agreement.
•Employee Matters Agreement — addresses employment, compensation, and benefits matters, including the allocation and treatment of assets and liabilities relating to employees and compensation and benefits plans and programs in which GRAIL employees participate, as well as the treatment of cash-based incentive awards in connection with the Spin-Off. See Note 5 — Stock-Based Compensation for further details regarding the treatment of equity awards.
•Stockholder and Registration Rights Agreement — governs the respective rights, responsibilities and obligations of Illumina and the Company after the Spin-Off with respect to Illumina’s continuing ownership of GRAIL common stock.
•Supply and Commercialization Agreement Amendment — amends the Company’s supply and commercialization agreement with Illumina, which governs the ongoing supply and commercial relationship, including licensing, royalty payments and intellectual property between GRAIL and Illumina. See Note 6 — Related Party Transactions for more information regarding the royalty arrangements with Illumina.
Illumina provided the Company with disposal funding (the “Disposal Funding”) in the amount of $932.3 million in accordance with the Separation and Distribution Agreement, subject to a clawback feature in the event
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
that the Company (i) consummates a change in control transaction, sells or licenses substantially all of its assets or adopts a plan of liquidation (collective, a “GRAIL Change of Control”), or (ii) (1) pays any dividend on, or makes any other distribution in respect of, any shares of its capital stock or other equity or voting interests (other than a stock dividend or a stock split), or otherwise consummates a return of capital from the Company to any of its equity holders or (2) redeems, purchases or otherwise acquires any of its outstanding shares of capital stock or other equity or voting interests (other than the acquisition of any shares in order to effectuate a “net settlement” transaction for the purposes of satisfying tax withholding obligations arising in connection with the grant, vesting, exercise and/or settlement of any outstanding incentive equity awards of GRAIL held by its current or former employees), in each case, prior to the September 24, 2025 (the 15-month anniversary of the Distribution Date). See Note 9 — Legal And Regulatory Proceedings — Contingencies for details.
Ability to Continue as a Going Concern
The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on, among other things, the Company’s ability to manage its net loss and to become profitable and operate profitably, to manage the Company’s negative cash flows from operations and to generate positive cash flows from operations, and the Company’s ability to obtain financing to support working capital requirements. The Company had $958.8 million of cash and cash equivalents as of June 30, 2024.
The Company believes that its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months, as of the date these condensed consolidated financial statements were filed.
As of June 30, 2024, the Company had no off-balance sheet concentrations of credit risk.
Fiscal Year
The Company has a fiscal year end of December 31. Prior to the Spin-Off, the Company’s fiscal year was the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. References to Q2 2023 refer to the three and six months ended July 2, 2023 which were 13 weeks and 26 weeks, respectively.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements represent the historical operations of the standalone GRAIL legal entity and include purchase accounting adjustments and certain tax adjustments as if the Company filed a separate income tax return and was not included in Illumina’s consolidated return for the period of time the Company was owned by Illumina. All revenues and costs as well as assets and liabilities directly associated with the business activity of the Company are included in the unaudited condensed consolidated financial statements. Certain assets and liabilities were reflected at fair value under the new basis of accounting established at the closing of Illumina’s acquisition of the Company in August 2021 (“the Acquisition”).
Management considered the need to allocate any historical shared costs incurred by the parent, Illumina, to the accompanying condensed consolidated financial statements. As previously discussed, the European Commission adopted an order requiring Illumina and GRAIL to be held and operated as distinct and separate entities. As no integration ever occurred, management concluded that no material allocations were required. As of December 31, 2023, the Company had generated net operating loss carryforwards for federal and state tax purposes of $3.5 billion and $2.3 billion, respectively. As a single member LLC disregarded for tax purposes, these tax attributes are the sole property of Illumina and remained the assets of Illumina following the Spin-off in accordance with the Internal Revenue Code. However, amounts recognized by the Company are not necessarily representative of the amounts that would have been reflected in the financial statements had the Company
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
operated independently of the parent. Related party transactions with Illumina are discussed further in Note 6 — Related Party Transactions.
These unaudited condensed consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”), reflect all normal recurring adjustments that are necessary to present the results fairly, and include the accounts of the Company and its wholly owned subsidiaries for the interim periods presented. All intercompany balances have been eliminated in consolidation.
Significant Accounting Policies
The significant accounting policies used in preparation of these unaudited condensed combined financial statements for the three and six months ended June 30, 2024 and July 2, 2023 are consistent with those discussed in Note 2 — Summary of Significant Accounting Policies, within the consolidated financial statements for the year ended December 31, 2023 included in the Form 10, except as described below.
Stock-Based Compensation Expense
The Company’s stock-based compensation expense includes expenses related to cash-based equity incentive awards, restricted stock units (“RSUs”), and performance stock options. Forfeitures are accounted for as incurred.
In connection with the Spin-Off, GRAIL and Illumina entered into an Employee Matters Agreement pursuant to which the Company’s equity awards were modified (the “Award Modification”). A cash-based equity incentive award (the “Cash-Based Equity Award”) program was adopted following Illumina’s acquisition of GRAIL in 2021 to provide GRAIL employees with dollar-denominated long-term incentive awards. The cash-settled, liability-classified awards were modified to become RSUs that will be settled in shares of the Company’s common stock upon vesting. Unvested performance stock options that were previously held by certain GRAIL employees to purchase Illumina common stock were also converted to options to purchase GRAIL common stock in connection with the Spin-Off. See Note 5 — Stock-Based Compensation for further details of the Award Modification.
Prior to the Award Modification, the Cash-Based Equity Awards were liability-classified awards because the Cash-Based Equity Awards could be settled in cash. Until April 30, 2024, GRAIL’s stand-alone value calculation was estimated by the Company based on its analysis and the input from independent valuation advisors. The value of the Cash-Based Equity Awards was recorded over the applicable vesting periods, with recognition of a corresponding liability recorded in incentive plan liabilities in the consolidated balance sheets. The Cash-Based Equity Awards were remeasured at each reporting date until settlement with changes in fair value recognized in stock-based compensation expense. On April 30, 2024, Illumina’s Compensation Committee approved an adjustment of the ordinary course payouts of the Cash-Based Equity Awards providing that the Cash-Based Equity Awards would be paid based on their nominal (face) value without adjustment based on changes in equity value. Subsequent to this adjustment to the Cash-Based Equity Awards and continuing until the Award Modification, the Cash-Based Equity Awards were expensed in accordance with their applicable vesting schedules.
The grant date fair value of RSUs are determined based on the closing market price of GRAIL’s common stock on the date of the grant (in the case of RSUs resulting from the Award Modification, the date of the Award Modification). Stock-based compensation expense is recognized based on the fair value on a straight-line basis over the requisite service periods of the RSUs.
The fair value of performance stock options with service conditions is determined using the Black-Scholes-Merton option-pricing model. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The expected volatility is generally determined by weighing the historical and implied volatility of peer companies’ common stock. The expected term is the Company’s best estimates based on the vesting period and contractual term. Given that cash dividends were never declared or paid on the Illumina nor GRAIL common stock, the expected dividend yield is determined to be 0%. The Company does not anticipate paying cash dividends in the foreseeable future. The risk-free interest rate is based upon U.S. Treasury securities with
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
remaining terms similar to the expected term of the stock-based awards. The fair value of the performance stock options begins to be recognized when it is probable that the performance-based condition will be met.
Provision for (Benefit from) Income Taxes
As a standalone entity, the Company files tax returns on its own behalf, and tax balances and the effective income tax rate may differ from the amounts reported in historical periods. As of June 24, 2024 and in connection with the Spin-Off, the Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity. During the period that Illumina held the Company, the Company’s activity generated various tax attributes recognized as deferred tax assets (“DTAs”), due primarily to the generation of net operating losses (“NOLs”), IRC 174 capitalized research and experimental expenditures, and research and development (“R&D”) tax credits that could not be specifically utilized by the Company as it did not generate positive taxable income and it was not a separately regarded tax paying entity from Illumina. Since the Company was not a separately regarded taxable entity from Illumina, these tax attributes were either utilized by or will be utilized by Illumina when filing its consolidated tax return. Historically, the tax attributes were only presented in the Company’s stand-alone financial statements to allow the users to understand the financial position of the Company as a stand-alone taxable entity under the Separate-Return Method. The total tax-effected value of the tax attributes, net of Financial Accounting Standards Board Interpretation No. 48 (“FIN48”) liabilities and valuation allowance that were deemed to be the property of Illumina, was $447.2 million. In connection with the Spin-off, the underlying $447.2 million of tax attributes were adjusted through an entry of $447.2 million to additional paid in capital.
Net Loss Per Share Attributable to Common Stockholders
The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. In loss periods, basic and diluted net loss per share are identical since the effect of potentially dilutive common shares is antidilutive and therefore excluded. Potentially dilutive common shares consist of shares issuable under equity awards. Potentially dilutive common shares from equity awards are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares.
Cash Equivalents
As of June 30, 2024 and December 31, 2023, the Company’s cash equivalents were held in money market funds, totaling $955.9 million and $92.6 million, respectively. In connection with the consummation of the Spin-Off, in June 2024, Illumina provided disposal funding of $932.3 million to the Company in accordance with the Separation and Distribution Agreement. Cash equivalents held in money market funds were categorized as Level 1 investments within the fair value hierarchy.
Except for the accounting policies described above, there were no changes to the Company’s significant accounting policies during the three months ended June 30, 2024 as described in Note 2 — Summary of Significant Accounting Policies to the Company’s audited Consolidated Financial Statements filed with its Form 10 Registration Statement on June 3, 2024.
Concentration Risk
The Company had sales to a single customer that accounted for approximately 10% of total sales for the three and six months ended June 30, 2024 and 10% of total sales for the six months ended July 2, 2023. Amounts
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
due from this same single customer represented approximately 19% and 43% as of June 30, 2024 and December 31, 2023, respectively.
Recently Adopted Accounting Pronouncements
The Company evaluates all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the "FASB") for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.
Accounting Pronouncements Not Yet Adopted
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. This guidance will be effective for the annual reporting periods beginning the year ended December 31, 2024, and for interim reporting periods beginning January 1, 2025, with early adoption permitted, and should be applied retrospectively. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. This guidance will be effective for annual reporting periods beginning the year ended December 31, 2025, with early adoption permitted and can be applied on either a prospective or retroactive basis. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements.
NOTE 3. GOODWILL AND INTANGIBLE ASSETS
Due to the application of pushdown accounting, the Company’s balance sheet includes goodwill and intangible assets recognized by Illumina in connection with Illumina’s acquisition of the Company.
Goodwill Impairment
Goodwill represents the excess of purchase price Illumina paid over the fair value of the net identifiable assets acquired upon the acquisition of the Company.
During Q2 2024, prior to the Spin-Off, the approval of the Spin-Off by Illumina’s board of directors represented a potential indicator of impairment, which also aligned with the timing of Illumina’s annual goodwill impairment test date for 2024. The assessment was performed using a market approach to determine the fair value of goodwill which utilized the valuation ranges prepared by the divestment financial advisors engaged by Illumina in connection with the Spin-Off. The valuation ranges were determined using revenue multiples from public company peers for 2024 and 2025. The implied discount rate for the goodwill impairment assessment was 51.5%. These estimates and assumptions represent a Level 3 measurement because they include unobservable inputs that are supported by little or no market activity and reflect Company-determined and judgmental factors for these assumptions in measuring fair value. The assumptions in the assessment of an impairment analysis are inherently subjective due to uncertainty and any slight changes in these rates and assumptions could have a significant impact on the concluded value of goodwill.
The Company recognized a goodwill impairment of $888.9 million as a result of the impairment assessment, primarily due to changes to the forecast of GRAIL’s value and the method for valuing GRAIL.
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Intangible Assets
Intangible assets identified in the Acquisition include trade names, developed technology, and in-process research and development (“IPR&D”) and were measured at fair value as of the closing date of Illumina’s acquisition of the Company (“Closing Date”).
| | | | | | | | | | | | | | | | | | | | | | | |
| June 30, 2024 |
(in thousands) | Gross Carrying Amount | | Accumulated Amortization | | Impairment | | Net Intangible Assets |
Developed Technologies | $ | 2,410,000 | | | $ | (379,352) | | | $ | — | | | $ | 2,030,648 | |
Trade Names | 40,000 | | | (12,592) | | | — | | | 27,408 | |
Total Finite-Lived Intangible Assets | 2,450,000 | | | (391,944) | | | — | | | 2,058,056 | |
In-process Research and Development (IPR&D) | 560,000 | | | — | | | (532,000) | | | 28,000 | |
Total Intangible Assets | $ | 3,010,000 | | | $ | (391,944) | | | $ | (532,000) | | | $ | 2,086,056 | |
| | | | | | | |
| December 31, 2023 |
(in thousands) | Gross Carrying Amount | | Accumulated Amortization | | Impairment | | Net Intangible Assets |
Developed Technologies | $ | 2,410,000 | | | $ | (312,408) | | | $ | — | | | $ | 2,097,592 | |
Trade Names | 40,000 | | | (10,369) | | | — | | | 29,631 | |
Total Finite-Lived Intangible Assets | 2,450,000 | | | (322,777) | | | — | | | 2,127,223 | |
In-process Research and Development (IPR&D) | 670,000 | | | — | | | (110,000) | | | 560,000 | |
Total Intangible Assets | $ | 3,120,000 | | | $ | (322,777) | | | $ | (110,000) | | | $ | 2,687,223 | |
The fair values of the developed technologies, trade names and IPR&D were estimated using an income approach, under which an intangible asset’s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair values were developed by discounting future net cash flows to their present value at market-based rates of return and inclusive of an assumption for technology obsolescence. The useful lives of the intangible assets for amortization purposes were determined by considering the period of expected cash flows used to measure the fair values of the intangible assets, adjusted as appropriate for entity-specific factors including legal, regulatory, contractual, competitive, economic, and other factors that may limit the useful life. The developed technology and trade names assets are amortized on a straight-line basis over their estimated useful lives.
In conjunction with Illumina’s Q2 2024 goodwill impairment assessment, the IPR&D intangible asset of the GRAIL reporting unit was evaluated for potential impairment by Illumina prior to the Spin-Off. The evaluation for a potential impairment of the IPR&D intangible asset was performed by comparing its carrying value to the assessed estimated fair value, which was determined by the income approach, using a discounted cash flow model. Estimates and assumptions used in the income approach included projected cash flows and a discount rate. The discount rate selected at the time of the IPR&D intangible impairment assessment was 46.5%. Based on the impairment test performed, Illumina assessed and determined that the carrying value of GRAIL’s IPR&D intangible asset exceeded its estimated fair value. As a result of push down accounting, the Company recognized an impairment of $420.0 million primarily due to changes to revenue projections and the discount rate utilized.
Subsequent to the Spin-Off, the Company performed a portfolio review and determined to decrease investment in the development of the IPR&D asset, which impacted the amount and timing of expected future cash flows attributable to IPR&D. This determination was driven by the impact of our post-Spin-Off capital structure, constitution of our Board at the time of the Spin-Off as the key decision maker for the determination, and increased ability to revisit our business strategy and portfolio as a standalone public company without regulatory oversight. This represented a potential impairment indicator. An impairment assessment was performed using a discounted cash flow model utilizing the updated projected cash flows and discount rate. The discount rate selected was 20%. Based on the impairment test performed, the Company assessed and determined that the carrying value of the IPR&D intangible asset exceeded its estimated fair value. As a result, the Company recognized an additional impairment of $112.0 million, primarily due to a decrease in projected cash flows. As of
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
June 30, 2024, the IPR&D intangible asset had a remaining balance of $28.0 million and had not been completed or abandoned. The IPR&D intangible asset is not currently subject to amortization.
The estimates and assumptions updated in each of these evaluations represent a Level 3 measurement because they include unobservable inputs that are supported by little or no market activity and reflect Company- determined and judgmental factors for these assumptions in measuring a fair value. The assumptions in the assessment of an impairment analysis are inherently subjective due to uncertainty and any slight changes in these rates and assumptions could have a significant impact on the concluded value of the IPR&D intangible asset.
A recoverability test for the finite-lived intangible assets, which includes developed technology and trade names, was also performed. Based on the assessment performed, no impairment was noted for the finite-lived intangibles.
The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.
| | | | | |
(in thousands) | Estimated Annual Amortization |
Remainder of 2024 | $ | 69,166 | |
2025 | 138,333 | |
2026 | 138,333 | |
2027 | 138,333 | |
2028 | 138,333 | |
2029 | 138,333 | |
Thereafter | 1,297,225 | |
Total | $ | 2,058,056 |
NOTE 4. BALANCE SHEET COMPONENTS
The following tables present financial information of certain condensed consolidated balance sheets components:
| | | | | | | | | | | |
Accounts receivable, net | June 30, 2024 | | December 31, 2023 |
(in thousands) | | | |
Trade accounts receivable, gross | $ | 16,465 | | | $ | 19,924 | |
Allowance for credit losses | (3,091) | | | (3,062) | |
Total accounts receivable, net | $ | 13,374 | | | $ | 16,862 | |
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
| | | | | | | | | | | |
Prepaid expenses and other current assets | June 30, 2024 | | December 31, 2023 |
(in thousands) | | | |
Prepaid service and maintenance | $ | 2,218 | | | $ | 1,179 | |
Prepaid software | 6,590 | | | 4,734 | |
Prepaid insurance | 247 | | | 814 | |
Prepaid other | 6,486 | | | 6,579 | |
Tax receivable | 4,160 | | | 5,411 | |
Indirect taxes | 1,165 | | | 1,383 | |
Total prepaid expenses and other current assets | $ | 20,866 | | | $ | 20,100 | |
| | | | | | | | | | | |
Accrued liabilities | June 30, 2024 | | December 31, 2023 |
(in thousands) | | | |
Accrued compensation expenses | $ | 31,738 | | | $ | 41,484 | |
Accrued legal and professional expenses | 3,180 | | | 7,770 | |
Accrued clinical studies expenses | 6,475 | | | 6,897 | |
Accrued research and development expenses | 6,258 | | | 6,647 | |
Accrued marketing | 650 | | | 1,882 | |
Accrued other expenses | 8,272 | | | 9,031 | |
Total accrued liabilities | $ | 56,573 | | | $ | 73,711 | |
NOTE 5. STOCK-BASED COMPENSATION
Stock-based compensation expense, which includes expense for both equity and liability-classified awards, reported in the condensed consolidated statements of operations, was as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended |
(in thousands) | June 30, 2024 | | July 2, 2023 | | June 30, 2024 | | July 2, 2023 |
Cost of screening revenue (exclusive of amortization of intangible assets) | $ | 451 | | | $ | 446 | | | $ | 921 | | | $ | 819 | |
Cost of development services revenue | 12 | | | 4 | | | 23 | | | 4 | |
Research and development | 9,625 | | | 10,343 | | | 21,068 | | | 19,303 | |
Sales and marketing | 4,889 | | | 4,844 | | | 10,352 | | | 8,886 | |
General and administrative | 10,970 | | | 9,912 | | | 22,689 | | | 18,053 | |
Stock-based compensation expense, before taxes | 25,947 | | | 25,549 | | | 55,053 | | | 47,065 | |
Related income tax benefits | (6,300) | | | (6,163) | | | (13,368) | | | (11,353) | |
Stock-based compensation expense, net of taxes | $ | 19,647 | | | $ | 19,386 | | | $ | 41,685 | | | $ | 35,712 | |
2024 Incentive Award Plan
The GRAIL, Inc. 2024 Incentive Award Plan (the “2024 Plan”) was adopted by GRAIL and approved by Illumina, in its capacity as GRAIL’s sole stockholder, in May 2024 to facilitate the grant of cash and equity incentive awards to non-employee directors, employees, and consultants of the Company and its subsidiaries and to enhance the ability of the Company and any of its subsidiaries to obtain and retain the services of these individuals following the Spin-Off. This plan authorizes the issuance of stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalents, performance-based awards, and other stock or cash based awards. The maximum number of shares authorized for issuance under the 2024 Plan is the sum of (a)
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
8,656,817 shares; and (b) annual increase on the first day of each calendar year beginning on and including January 1, 2025 and ending on and including January 1, 2034, equal to the lesser of (i) 5% of the aggregate number of shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the GRAIL board of directors. As of June 30, 2024, approximately 2.1 million shares remained available for future grants under the 2024 Plan.
A summary of the Company’s restricted stock unit activity is as follows:
| | | | | | | | | | | |
| Restricted Stock Units | | Weighted-Average Grant-Date Fair Value Per Share |
(Units in thousands) | | | |
Outstanding at January 1, 2024 | — | | $— |
Conversion | 6,485 | | $15.37 |
Awarded | 79 | | $17.00 |
Vested | — | | $— |
Cancelled | — | | $— |
Outstanding at June 30, 2024 | 6,564 | | $15.39 |
2024 Employee Stock Purchase Program
The GRAIL, Inc. 2024 Employee Stock Purchase Plan (the “ESPP”) was adopted by GRAIL and approved by Illumina, in its capacity as GRAIL’s sole stockholder, in May 2024. As previously disclosed in the Information Statement, the number of shares of Company common stock initially available under the ESPP is equal to (a) 414,021 (b) an annual increase on the first day of each calendar year beginning on and including January 1, 2025 and ending on and including January 1, 2034, equal to the lesser of (i) 1% of the aggregate number of shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the GRAIL board of directors. There are 0.4 million shares of Company common stock initially available for issuance pursuant to the ESPP. As of June 30, 2024, no shares had been granted under the ESPP plan.
2024 Transition Incentive Award
During the second quarter of 2024, one-time cash-based incentive awards were granted to GRAIL employees, including executives, for retention purposes (“2024 Transition Incentive Awards”) with a total grant date fair value of $40.2 million which were treated as a liability-classified awards. Each award vests entirely in one year or less from its grant date, subject to the applicable holder’s continued service through the vesting date or, if earlier upon (i) the applicable holder’s termination due to death or disability or (ii) following a “change in control” (as defined in the award agreement evidencing the 2024 Transition Incentive Award), the applicable holder’s termination without “cause” or for “good reason” (each as defined in the award agreement evidencing the 2024 Transition Incentive Award). In connection with the Spin-Off, the 2024 Transition Incentive Awards were converted into GRAIL RSUs in accordance with the Employee Matters Agreement by dividing the aggregate award value by the volume-weighted average share price over the first four trading days following the Spin-Off. On the modification date, June 28, 2024, the liability-classified awards in the amount of $4.4 million were reclassified to Additional Paid-In Capital. As the result of this modification, the 2024 Transition Incentive Awards that were outstanding on the Distribution Date were converted into GRAIL RSUs covering 2.5 million shares.
Cash-Based Equity Awards
The Cash-Based Equity Award program was adopted following Illumina’s acquisition of GRAIL in 2021 to provide GRAIL employees with dollar-denominated long-term incentive awards that increased or decreased in value based on corresponding changes in GRAIL’s calculated value. GRAIL’s stand-alone value calculation was estimated by the Company based on its analysis and on input from independent valuation advisors. To estimate
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
the value of GRAIL for the purposes of the Cash-Based Equity Awards, various assumptions were used, including long-range financial projections, as well as the discount rate and terminal growth rate. The awards generally vested in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. In April 2024, Illumina’s Compensation Committee and Board of Directors (as applicable) approved an adjustment of the ordinary course payouts for all outstanding Cash-Based Equity Awards providing that the Cash-Based Equity Awards would be paid based on their nominal (face) values without adjustment based on changes in equity value. Subsequent to this adjustment to the Cash-Based Equity Awards and continuing until the Award Modification, the Cash-Based Equity Awards were expensed based on such nominal (face) value in accordance with their applicable vesting schedules. The payments in respect of the Cash-Based Equity Awards between the adoption of such adjustment and the Distribution Date were paid out in cash at the applicable Cash-Based Equity Awards’ nominal (face) value. Payments in respect of the Cash-Based Equity Awards before such adjustment were paid out in cash based on the adjusted value of the Cash-Based Equity Award on the applicable vesting date.
In connection with the Spin-Off, outstanding Cash-Based Equity Awards were modified and converted into GRAIL RSUs in accordance with the Employee Matters Agreement determined by dividing the Aggregate Award Value (as discussed below) for such Cash-Based Equity Award by the volume-weighted average share price of GRAIL stock on the first four trading days following the Spin-Off. All other terms and conditions of the awards, including vesting and payment terms, were unaffected by the conversion. All other terms and conditions of the awards, including vesting and payment terms, were unaffected by the conversion.
For each Cash-Based Equity Award, the “Aggregate Award Value” is equal to, (i) for the portion of such award originally scheduled to vest in 2024, the initial grant value of such portion, and (ii) for the remaining unvested portion of such award, the initial grant value of such portion adjusted up or down based on a percentage, with such percentage determined by (A) GRAIL’s average closing market capitalization for the four trading days immediately following the distribution date minus the aggregate equity value of GRAIL at the time the Cash-Based Equity Award was granted, as reflected in the consolidated financial statements of Illumina (the “Baseline Equity Value”), divided by (B) the Baseline Equity Value.
Upon modification, the awards became equity-classified. The value of tranches of the Cash-Based Equity Awards that vest in future years (exclusive of the 2024 Transition Incentive Awards described above) was reduced and, as a result, there was no incremental compensation cost. Approximately 1,300 grantees were impacted by this modification. On the modification date, June 28, 2024, the liability-classified awards were reclassified to Additional Paid-In Capital at their fair value in the amount of $50.3 million. Due to the higher value of the 2024 tranche of the Cash-Based Equity Awards, compensation cost will be recognized over the vesting period to ensure compensation cost has been recognized at least equal to the amount that is legally vested. As the result of this modification, the Cash-Based Equity Awards that were outstanding on the Distribution Date were converted to 4.0 million RSUs to be settled in GRAIL shares.
Cash-Based Equity Award activity was as follows:
| | | | | |
(in thousands) | |
Beginning balance December 31, 2023 | $ | 292,189 | |
Granted | 66,864 | |
Cancelled | (11,751) | |
Vested and paid in cash | (53,807) | |
Change in fair value | (9,535) | |
Outstanding balance, June 28, 2024 (Award Modification Date) | $ | 283,960 | |
Conversion of outstanding awards to GRAIL RSUs | (283,960) | |
Outstanding balance, June 30, 2024 | $ | — | |
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Performance-Based Award
The Company has one performance-based award outstanding for a former employee for which vesting is based on future revenues. The award has an aggregate potential value of up to $78.0 million and expires, to the extent unvested, in August 2030. One-fourth of the total potential value of the award vests immediately upon the achievement of cumulative net revenues in any period of four consecutive fiscal quarters of $500.0 million, $750.0 million, $1.5 billion, and $2.0 billion. The Company assesses the probability of achieving the performance conditions associated with the award on a quarterly basis at each reporting period. If and to the extent that the liability becomes due and payable prior to 12:01 a.m. Eastern Time December 24, 2026 (the “Disposal Funding Period”) and paid by GRAIL, in cash, during the Disposal Funding Period, Illumina shall reimburse GRAIL all or such portion of the liability paid by GRAIL in accordance of the terms of the Separation and Distribution Agreement. As of June 30, 2024, it was not probable that the performance conditions associated with the award will be achieved and, therefore, no stock-based compensation expense, or corresponding loss recovery asset or liability, has been recognized in the condensed consolidated financial statements.
Performance Options
In connection with the Spin-Off, unvested performance-based stock options previously issued to GRAIL employees to purchase Illumina common stock were converted into performance-based stock options to purchase GRAIL common stock (“Performance Options”) in accordance with the Employee Matters Agreement. As of the Distribution Date, there were two remaining unvested Performance Options. On June 28, 2024, the modification date, the Company accounted for the modification of these two Performance Options as Type I and Type IV modifications, respectively. These options were converted at a ratio equal to the average of the volume weighted average per share price of Illumina stock trading during the four days immediately preceding the Distribution Date divided by the average of volume weighted average per share price of GRAIL common stock on the first four trading days immediately following the Distribution Date. For the Performance Option with Type I modification, the incremental charge recognized of the difference in the fair value of the option before and immediately after the modification was immaterial. As the result of this modification, the Performance Options that were outstanding on the Distribution Date were converted to 0.1 million options which remain outstanding as of June 30, 2024. For the Performance Option with Type IV modification, the fair value of the award as of the Modification Date will be used for expense purposes once the award becomes probable of achievement.
As of June 30, 2024, approximately $2.2 million of total unrecognized compensation cost related to the Performance Options was expected to be recognized over a period of approximately 3.2 years. There were no outstanding Performance Options exercisable as of June 30, 2024. The aggregate intrinsic value of the Performance Options outstanding as of June 30, 2024 and December 31, 2023 was $0.2 million and $0.9 million, respectively. The outstanding Performance Options, in general, have contractual terms of ten years from the respective grant dates. The Performance Options generally vest monthly over three years upon the achievement of Company-specified performance targets and are subject to continued service through the applicable vesting date.
NOTE 6. RELATED PARTY TRANSACTIONS
Illumina Purchases and Sales
The Company was a subsidiary of Illumina, Inc. between August 19, 2021 to June 23, 2024. Subsequent to the Spin-Off, Illumina retained a 14.5% stake in the Company. Illumina is both a customer of the Company and a major supplier of the Company’s reagents and capital equipment. Goods and services transactions with Illumina are invoiced and paid when due.
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Goods and services transactions with Illumina have been reflected in the condensed consolidated financial statements as follows:
| | | | | | | | | | | |
(in thousands) | As of June 30, 2024 | | As of December 31, 2023 |
Accounts receivable, net — related parties | $ | 32 | | | $ | 80 | |
Supplies — related parties | 6,259 | | | 5,855 | |
Prepaid expenses and other current assets — related parties | 59 | | | 41 | |
Property and equipment, net — related parties | 3,021 | | | 3,640 | |
Accounts payable — related parties | — | | | 168 | |
Accrued liabilities — related parties | — | | | 95 | |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended |
(in thousands) | June 30, 2024 | | July 2, 2023 | | June 30, 2024 | | July 2, 2023 |
Screening revenue — related parties | $ | 108 | | | $ | 164 | | | $ | 237 | | | $ | 416 | |
Cost of screening revenue — related parties | 3,457 | | | 2,213 | | | 6,126 | | | 3,792 | |
Cost of development services revenue — related parties | 71 | | | 36 | | | 116 | | | 60 | |
Operating expenses — Research and development — related parties | 5,310 | | | 6,386 | | | 10,112 | | | 11,166 | |
Operating expenses — General and administrative — related parties | 52 | | | 52 | | | 103 | | | 103 | |
The Company has entered into an amendment to its Supply and Commercialization Agreement with Illumina. Under the terms of the amended agreement, regardless of whether its products incorporate any Illumina technology, the Company has agreed to pay to Illumina a high single-digit royalty, subject to certain reductions, in perpetuity on net sales generated by its products or revenues otherwise generated or received by the Company, subject to certain exceptions, in the field of oncology. Per the terms of the Separation and Distribution Agreement with Illumina, the royalty arrangement is suspended until the earlier of December 24, 2026 or any earlier change of control of the Company, at which time a high-single digit royalty payments will be payable.
Contributions from Member, Net
The following related party transactions between the Company and Illumina have been included in these condensed consolidated financial statements. As there was no intercompany loan agreement between Illumina and GRAIL and because these transactions had no history of being settled and were not settled per the terms of the Separation and Distribution Agreement, the total net effect of these transactions are reflected in the condensed consolidated statements of cash flows as cash provided by financing activities and in the condensed consolidated balance sheets as contribution from member, net, in member’s equity. The following table presents the components of the net transfers to and from Illumina:
| | | | | | | | | | | |
| Six Months Ended |
(in thousands) | June 30, 2024 | | July 2, 2023 |
Cash funding received from Illumina | $ | 1,244,300 | | | $ | 304,000 | |
| | | |
| | | |
| | | |
Taxes paid related to net share settlement of equity awards | — | | | (225) | |
| | | |
Total contribution from member, net | $ | 1,244,300 | | | $ | 303,775 | |
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Twist Bioscience Relationship
Mr. Robert Ragusa was appointed as the Company’s chief executive officer in October 2021. Mr. Ragusa also serves on the board of directors of Twist Bioscience (“Twist”), a supplier to the Company. Transactions with Twist beginning when Mr. Ragusa became the Company’s chief executive officer are reflected in the condensed consolidated financial statements as related party transactions.
Related party transactions with Twist have been reflected in the condensed consolidated financial statements as follows:
| | | | | | | | | | | |
(in thousands) | As of June 30, 2024 | | As of December 31, 2023 |
Supplies — related parties | $ | 1,051 | | | $ | 1,052 | |
Accounts payable — related parties | — | | | 660 | |
| | | |
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended |
(in thousands) | June 30, 2024 | | July 2, 2023 | | June 30, 2024 | | July 2, 2023 |
Cost of screening revenue — related parties | $ | 322 | | | $ | — | | | $ | 385 | | | $ | — | |
Cost of development services revenue — related parties | 7 | | | — | | | 7 | | | — | |
Operating expenses — Research and development — related parties | 159 | | | 13 | | | 592 | | | 585 | |
NOTE 7. NET LOSS PER SHARE
Prior to the completion of the Spin-Off from Illumina, the Company had no common shares issued and outstanding. In connection with the Spin-Off, on June 24, 2024, there were 31.0 million shares of GRAIL common stock distributed to Illumina stockholders. This share amount is utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off. For the three and six months ended June 30, 2024 and July 2, 2023, these shares are treated as issued and outstanding for purposes of calculating historical earnings per share. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. For the three and six months ended June 30, 2024 and July 2, 2023 the amount of common stock equivalents excluded from the calculation of diluted net loss per share for the periods presented was 6.7 million shares of common stock equivalents.
The following table presents the calculation of the Company’s basic and diluted net loss per share attributable to common stockholders:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended |
(in thousands, except share and per share data) | June 30, 2024 | | July 2, 2023 | | June 30, 2024 | | July 2, 2023 |
Numerator | | | | | | | |
Net loss | $ | (1,585,337) | | | $ | (193,044) | | | $ | (1,804,251) | | | $ | (386,710) | |
Denominator | | | | | | | |
Weighted average shares of common stock—basic and diluted | 31,049,148 | | 31,049,148 | | 31,049,148 | | 31,049,148 |
Net loss per share attributable to common stockholders | | | | | | | |
Basic | $ | (51.06) | | | $(6.22) | | $ | (58.11) | | | $(12.45) |
Diluted | $ | (51.06) | | | $(6.22) | | $ | (58.11) | | | $(12.45) |
| | | | | | | |
| | | | | | | |
| | | | | | | |
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 8. TAXES
For interim financial statement purposes, U.S. GAAP provision (benefit) for taxes related to ordinary income is determined by applying an estimated annual effective income tax rate against a company’s ordinary income, subject to certain limitations on the benefit of losses. Provision (benefit) for taxes related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company’s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company’s estimated annual effective income tax rate may be revised, if necessary, in each interim period.
The worldwide effective income tax rates for the fiscal six months ended June 30, 2024 and July 2, 2023 were 3.37% and 4.41%, respectively. The decrease for the six months ended June 30, 2024 as compared to the six months ended July 2, 2023 primarily relates to the Company’s valuation allowance impacts against pre-tax losses prior to the Spin-off.
As discussed in Note 1 — Organization And Description Of Business and Note 2 — Summary Of Significant Accounting Policies — Basis of Presentation, prior to June 30, 2024, for tax purposes, the Company operated as a subsidiary of Illumina and not as a separately regarded taxable entity. Accordingly, the effective worldwide income tax rate for the six months ended July 2, 2023 was calculated using the separate return method as if the Company filed income tax returns on both a standalone basis and on a carve-out basis.
During the period that Illumina held the Company, the Company’s activity generated various tax attributes recognized as deferred tax assets (“DTAs”), due primarily to the generation of NOLs, IRC 174 capitalized research and experimental expenditures, and research and development (“R&D”) tax credits that could not be specifically utilized by the Company as it did not yet generate positive taxable income and it was not a separately regarded tax paying entity from Illumina. Because the Company was not a separately regarded taxable entity from Illumina, these tax attributes were either utilized by or will be utilized by Illumina when filing its consolidated tax return; therefore, the tax attributes were only presented in the Company’s stand-alone financial statements to allow the users to understand the financial position of the Company as a stand-alone taxable entity under the Separate-Return Method. The total tax-effected value of the tax attributes, net of FIN48 liabilities and valuation allowance that were deemed to be the property of Illumina, was $447.2 million. In connection with the Spin-off, the underlying $447.2 million of tax attributes were adjusted through an entry of $447.2 million to additional paid in capital.
NOTE 9. LEGAL AND REGULATORY PROCEEDINGS
The Company is subject to various claims, complaints, regulatory proceedings, and legal actions that arise from time to time in the ordinary course of business.
Antitrust and Competition Proceedings
On March 30, 2021, the U.S. Federal Trade Commission (“FTC”) issued an administrative complaint seeking to prevent the Acquisition. On September 1, 2022, an administrative law judge issued a decision in favor of the transaction and dismissed the FTC’s complaint. The FTC’s complaint counsel appealed to the full FTC Commission. On March 31, 2023, the FTC Commission issued a decision overturning the administrative law judge’s prior ruling. GRAIL and Illumina appealed the FTC’s decision to the U.S. Court of Appeals for the Fifth Circuit (“Fifth Circuit”). On December 15, 2023, the Fifth Circuit issued its opinion and order, in which the court ruled that the FTC applied the incorrect standard in assessing Illumina’s open offer contract and, on that basis, vacated the FTC order and remanded the case to the FTC for reconsideration of the effects of the open offer contract under the proper standard as described in the Fifth Circuit Court’s decision, and in all other respects upheld the FTC’s decision. The Company expects that completion of the Spin-Off will facilitate prompt resolution of the FTC proceedings. Based on the fact that Illumina had a 14.5% ownership interest in GRAIL at the time of the Acquisition, the Company does not expect that Illumina’s retention of a 14.5% ownership interest in GRAIL as a result of completion of the Spin-Off will affect the resolution of these proceedings.
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
On April 19, 2021, the European Commission accepted a request for a referral of the GRAIL, Inc. acquisition for European Union merger review, submitted by a Member State of the European Union (France), and joined by several other EEA Member States (Belgium, Greece, Iceland, the Netherlands, and Norway), under Article 22(1) of Council Regulation (EC) No 139/2004 (the “EU Merger Regulation”). On April 28, 2021, Illumina filed an action in the General Court of the European Union (the “EU General Court”) asking for annulment of the European Commission’s assertion of jurisdiction to review the acquisition under Article 22 of the EU Merger Regulation, as the acquisition does not meet the jurisdictional criteria under the EU Merger Regulation or under the national merger control laws of any Member State of the European Union. On July 13, 2022, the EU General Court confirmed the European Commission’s jurisdiction to examine the Acquisition (“EU General Court Article 22 Judgment”). On September 22 and 30, 2022, Illumina and the Company each asked for annulment of the EU General Court Article 22 Judgment and their appeal is currently pending before the Court of Justice of the European Union (“EU Court of Justice”). On March 21, 2024, the Advocate General recommended, in a non-binding Opinion, that the EU Court of Justice annul the General Court’s judgment and the European Commission’s decisions accepting the referral of the GRAIL acquisition for EU merger review. The EU Court of Justice is set to issue its ruling on September 3, 2024.
On October 29, 2021, the European Commission adopted an order imposing interim measures (the “Initial Interim Measures Order”). As the Initial Interim Measures Order was set to expire in 2022, the European Commission adopted new interim measures on October 28, 2022 (the “Second Interim Measures Order”). The Company and Illumina both sought the annulment of the Initial Interim Measures Order, and Illumina also sought the annulment of the Second Interim Measures Order (the Company intervened in this procedure in support of Illumina). All requests for annulment were stayed pending the appeal asking for annulment of the EU General Court Article 22 Judgment.
On September 6, 2022, the European Commission adopted a decision finding Illumina’s acquisition of GRAIL, Inc. incompatible with the internal market in the European Union. On November 17, 2022, Illumina asked for annulment of this decision before the EU General Court (the Company was admitted to intervene in support of Illumina).
On October 12, 2023, the European Commission adopted a decision requiring Illumina to divest the Company and to restore the situation prevailing before the Company’s acquisition by Illumina (the “EC Divestment Decision”). At the Spin-Off, Illumina provided the Company with the required capitalization (two-and-a-half years of funding based on the Company’s long-range plan). The order also permitted Illumina to maintain its royalty arrangement with the Company. On December 22, 2023, Illumina sought the annulment of the EC Divestment Decision before the EU General Court.
On December 17, 2023, following a review of the Fifth Circuit’s opinion, Illumina elected not to pursue further appeals of the decision and announced Illumina’s decision to divest GRAIL through a third-party sale or capital markets transaction. On December 22, 2023, Illumina submitted a divestment plan to the European Commission outlining proposed terms of the divestiture. The divestment plan, outlining the terms of the Company’s divestiture, was approved by the European Commission on April 12, 2024. On June 24, 2024, the Spin-Off was completed in accordance with the terms outlined in the divestment plan and completed the divestment of the Company required by the EC Divestment Decision.
With the completion of the Spin-Off, the Company expects that its role in and the significance to it of these matters will be substantially reduced.
Federal Securities Class Actions.
On November 11, 2023, the first of three securities class action complaints was filed against Illumina and certain of its current and former executive officers in the United States District Court for the Southern District of California. The first-filed case is captioned Kangas v. Illumina, Inc. et al., the second-filed case is captioned Roy v. Illumina, Inc. et al., and the third-filed case is captioned Louisiana Sheriffs’ Pension & Relief Fund v. Illumina, Inc. et al. (collectively, the “Actions”). The complaints generally allege, among other things, that defendants made materially false and misleading statements and omitted material facts relating to Illumina’s acquisition of Grail. The
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
complaints seek unspecified damages, interest, fees, and costs. On January 9, 2024, four movants filed motions to consolidate the Actions and to appoint a lead plaintiff (“Lead Plaintiff Motions”). On April 11, 2024, the Court issued an order consolidating the Actions into a single action (captioned in re Illumina, Inc. Securities Litigation No. 23-cv-2082-LL-MMP), and appointed Universal-Investment-Gesellschaft mbH, UI BVK Kapitalverwaltungsgesellschaft mbH, and ACATIS Investment Kapitalverwaltungsgesellschaft mbH as lead plaintiffs. (the “Lead Plaintiffs”). On June 21, 2024, the Lead Plaintiffs filed a consolidated amended complaint. The amended complaint alleges that GRAIL, in addition to Illumina, and certain of their respective current and former directors and others violated sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5 in connection with Illumina's acquisition of GRAIL and disclosures concerning the same. The Company denies the allegations in the complaints and intend to vigorously defend the litigation. In light of the fact that the lawsuits are in an early stage, the Company cannot predict the ultimate outcome of the suits.
Other Legal Matters
Legal matters include various claims, complaints, and legal actions that arise from time to time. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.
The company is involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to employment matters. In connection with these matters, the Company assesses, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the condensed consolidated financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Since litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. The Company regularly reviews outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures. The Company may change its estimates if its assessment of the various factors changes and the amount of ultimate loss may differ from estimates, resulting in a material effect on the Company’s business, financial condition, results of operations, and/or cash flows. As of June 30, 2024, there were no pending litigation with any probable losses that can be reasonably estimated.
Contingencies
Contingencies primarily correspond to claims arising in the ordinary course of business. If necessary, these contingencies will be accrued, to the extent believed to be reasonably estimable to resolve the matter. The accrued contingency amounts are included in other current liabilities. Should the Company not be able to secure the terms it expects, these estimates may change and will be recognized in the period in which they are identified.
In connection with the Spin-Off, Illumina provided the Company with disposal funding in the amount of $932.3 million in accordance with the Separation and Distribution Agreement, subject to a clawback feature. The clawback is triggered if, prior to September 24, 2025 (the 15-month anniversary of the Distribution Date), the Company (i) consummates a change in control of the Company or (ii) (1) pays any dividend on, or makes any other distribution in respect of, any shares of its capital stock or other equity or voting interests (other than a stock dividend or a stock split), or otherwise consummates a return of capital from GRAIL to any of its equity holders or (2) redeems, purchases or otherwise acquires any of its outstanding shares of capital stock or other equity or voting interests (other than the acquisition of any shares in order to effectuate a “net settlement” transaction for the purposes of satisfying tax withholding obligations arising in connection with the grant, vesting, exercise and/or settlement of any outstanding incentive equity awards of GRAIL held by its current or former employees). If the Company consummates a transaction described in the foregoing clause (i), the Company must return to Illumina a cash amount calculated by reference to the number of months which have elapsed since the Distribution Date at the time of the public announcement of the event giving rise to the change of control. If the Company consummates a transaction described in the foregoing clause (ii), the Company must return to Illumina a cash amount equal to the payments made by the Company in connection with such transaction. The amount of clawback payments made cannot exceed the amount of the initial disposal funding. As of June 30, 2024, no contingency liability was recorded as the contingency loss is not probable.
GRAIL, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
On June 21, 2024, in connection with the Spin-Off, Illumina and the Company also entered into the Tax Matters Agreement to govern the respective rights, responsibilities and obligations of Illumina and the Company after the Spin-Off with respect to all tax matters and will include restrictions to preserve the tax-free status of the Distribution. The Tax Matters Agreement included a number of restrictions on the Company to preserve the intended tax treatment of the Spin-Off. Breach of any covenant or representation contained in the Tax Matters Agreement will result in liability to specific separation taxes. As of June 30, 2024, as it was not probable that the Company will breach the agreement, no contingency liability was recorded in connection with the Tax Matters Agreement.
NOTE 10. SUBSEQUENT EVENTS
On August 9, 2024, following a portfolio review, the Company’s Board of Directors approved a restructuring plan (“Restructuring Plan”) designed to re-prioritize the Company’s resources to focus on its core MCED business and reduce overall spend as the Company progresses towards completion of registrational studies and premarket approval application (“PMA”) submission.
The Restructuring Plan includes a reduction in the Company’s existing headcount and planned 2024 hires of approximately 30%, inclusive of approximately 350 current full-time employees, or approximately 25% of the existing workforce as of June 30, 2024.
In connection with the Restructuring Plan to be effected in the third and fourth quarters of 2024, the Company estimates that it will incur a restructuring charge in Q3 2024 in the range of approximately $18 to $23 million which primarily consists of severance, benefits, payroll taxes, and other termination related costs, excluding an estimated net benefit in stock based compensation due to the reversal of previously recorded stock-based compensation expenses related to award cancellations.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our results of operations and financial condition together with our accompanying unaudited condensed consolidated financial statements and the notes thereto included under Item 1. “Financial Statements”. This discussion contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and our business and financial results. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed in the section entitled “Risk Factors” in Par II, Item 1A of this Form 10-Q and the section titled “Cautionary Statement Concerning Forward-Looking Statements” of this Quarterly Report on Form 10-Q.
Unless the context otherwise requires, references to "GRAIL," “we,” “us,” and the "Company" refer to (i) GRAIL, LLC and its consolidated subsidiaries prior to the Spin-Off as a carve-out business of Illumina and (ii) GRAIL, Inc. and its subsidiaries following the Spin-Off.
Overview
Our Business
We are an innovative commercial-stage healthcare company focused on saving lives and shifting the paradigm in early cancer detection. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our Galleri test is a commercially available screening test for early detection of multiple types of cancer, which we termed multi-cancer early detection (“MCED”). We believe Galleri is clinically validated based on the results of its clinical studies completed to date, including the results of its foundational case-control Circulating Cell-free Genome Atlas (“CCGA”) study and interventional PATHFINDER study which together enrolled more than 21,000 participants. In these studies, Galleri demonstrated an ability to detect a shared cancer signal across more than 50 types of cancer, accurately predict the specific organ or tissue type where the cancer signal originated, and yield high positive predictive values and low false positive rates, all from a simple blood draw. See “Business—Our Products: Galleri and Beyond” and “—Our Clinical Studies” sections of our final Information Statement filed with our Registration Statement on Form 10, as amended (the “Form 10”), as filed with the SEC. Galleri results can help guide next steps for diagnosis of cancer by healthcare providers in required follow-up diagnostic testing. Galleri is not a diagnostic test and has not been approved or cleared by the U.S. Food and Drug Administration. We launched Galleri in the United States in mid-2021. As of June 30, 2024, we have sold more than 215,000 commercial tests and established over 140 commercial partnerships, including leading healthcare systems, employers, payors, and life insurance providers. Commercial use of Galleri has detected some of the most aggressive cancers in early stages including, among others, endometrial, esophageal, gastrointestinal stromal, head and neck, liver, pancreatic, and rectal cancers.
Since our inception, we have incurred net losses each year. We incurred net losses of $1.6 billion and $193.0 million for the three months ended June 30, 2024 and July 2, 2023, respectively and $1.8 billion and $386.7 million for the six months ended June 30, 2024 and July 2, 2023, respectively (see “Basis of Presentation” below for a description of applicable fiscal periods). Adjusted EBITDA was $(139.4) million and $(136.5) million for the three months ended June 30, 2024 and July 2, 2023, respectively and $(291.4) million and $(274.3) million for the six months ended June 30, 2024 and July 2, 2023, respectively. Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most directly comparable U.S. generally accepted accounting principle (“GAAP”) financial measure, information about why we consider Adjusted EBITDA useful and a discussion of the material risks and limitations of these measures, please see “Non-GAAP Financial Measures” below. Substantially all of our net losses resulted from the application of pushdown accounting, including goodwill and intangible asset impairment, amortization of intangible assets, as well as our research and development programs, general and administrative (“G&A”) expenses associated with our operations and sales and marketing costs associated with commercializing our products. Additionally, due to the application of pushdown accounting, our balance sheet included goodwill and includes intangible assets recognized by Illumina in connection with their acquisition of us that may be subject to additional impairment over time. We expect to continue to incur operating losses over at least the next several years as we continue to invest in research and development of new and existing products.
Separation from Illumina
On June 24, 2024, Illumina completed the previously announced spin-off of GRAIL (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 85.5% of our outstanding common stock to the holders of record of Illumina’s common stock as of the close of business on June 13, 2024 (the “Distribution”, which resulted in the issuance of 31,049,148 shares of common stock. As a result of this Distribution, GRAIL became an independent public entity. GRAIL’s common stock is listed under the ticker symbol “GRAL” on the NASDAQ Stock Exchange.
We entered into or adopted agreements that provide a framework for the relationship between us and Illumina in connection with the Spin-Off. See Note 1 — Organization And Description Of Business for details. In connection with the Spin-Off, certain equity and liability classified awards were converted in accordance with the employee matters agreement, as further described in Note 5 — Stock-Based Compensation. As a result of the separation, our member’s equity balance was reclassified to additional paid-in capital.
On June 21, 2024, in connection with the Spin-Off, we received a cash contribution of $932.3 million from Illumina. In connection with the Spin-Off, we incurred $21.9 million of legal and professional fees in the six month period ended June 30, 2024 related to the 2021 acquisition of GRAIL by Illumina, and corresponding antitrust litigation, including compliance with the hold separate arrangements imposed by the European Commission, and and divestiture of GRAIL from Illumina through the Spin-Off. See “Non-GAAP Financial Measures — Adjusted EBITDA” for further details. In addition, from 2021 to 2023, we spent $121.7 million on legal and professional service fees related to the antitrust litigation and compliance with the hold separate order and transaction costs related to Illumina’s acquisition of GRAIL and the Spin-Off.
Restructuring Plan
On August 9, 2024, following a portfolio review, our Board of Directors (the “Board”) approved a restructuring plan (“Restructuring Plan”) designed to reprioritize our resources to focus on our core MCED business and reduce overall spend as we progress towards completion of registrational studies and premarket approval application (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”)for Galleri.
As a result, we are streamlining our commercial sales forces and focusing its field-based activities on the current customers expected to be more productive and high priority opportunities. We are maintaining sales force coverage for the majority of our current Galleri volume and active prescribers. As part of this approach,we are also streamlining investments in its enterprise business, which includes our employer and life insurance businesses. Reductions in the commercial organization include management layers and commercial roles without sales responsibilities. In addition to reductions in the commercial organization, we are making reductions in medical affairs teams involved with U.S. Galleri provider engagement.
We are substantially decreasing investment in research and development activities related to our product programs beyond Galleri, including our diagnostic aid for cancer and minimal residual disease programs. In addition, we are making reductions in general and administrative expenses to reflect the focus on the MCED opportunity. We plan to continue to invest in our biopharmaceutical partnerships and work with our partners to leverage our proprietary methylation technology in precision oncology applications.
The Board’s decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses and maximize shareholder value.
The Restructuring Plan includes a reduction in our existing headcount and planned 2024 hires of approximately 30%, inclusive of 350 current full-time employees, or approximately 25% of the existing workforce as of June 30, 2024.
In connection with the Restructuring Plan to be effected in the third and fourth quarters of 2024, we estimate that we will incur a restructuring charge in Q3 2024 in the range of approximately $18 to $23 million which consists of severance, benefits, payroll taxes, and other termination related costs, excluding an estimated net benefit in stock based compensation due to the reversal of previously recorded stock-based compensation expenses related to award cancellations. We expect the headcount reductions to enable future cost savings of
approximately $120 million on an annual basis, with approximately $27 million in savings, net of severance and benefits, in 2024. We estimate that the Restructuring Plan extends our anticipated cash runway from the second half of 2026 into 2028.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared on a stand-alone basis using the consolidated financial statements and accounting records of Illumina prior to the Spin-Off. Since the Spin-Off, we present our financial statements on a consolidated basis as a standalone publicly traded company. These unaudited condensed consolidated financial statements reflect our consolidated historical financial position, results of operations and cash flows as historically managed, in accordance with GAAP. The unaudited condensed consolidated financial statements may not be indicative of our future performance and do not necessarily reflect what the financial position, results of operations and cash flows would have been, and may not include all expenses that would have been incurred, had GRAIL been operated as an independent, publicly traded company during the periods presented prior to the Spin-Off. Certain situations require management to make estimates based on judgments and assumptions, which may affect the reported amounts of assets and respective disclosures at the date of the financial statements. Management’s judgments and assumptions may also affect the reported amounts of net sales and expenses during the reporting periods. Actual results could differ from these management estimates.
While GRAIL was a subsidiary of Illumina, GRAIL’s fiscal year was the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. References to Q2 2024 and Q2 2023 refer to the three and six months ended June 30, 2024 and July 2, 2023, respectively, which were both 13 weeks. Upon the closing of the Spin-Off, GRAIL adopted a fiscal year end of December 31.
Illumina’s acquisition of GRAIL on August 18, 2021 (“the Acquisition”) represented a change of control with respect to GRAIL. Given GRAIL, Inc. merged with SDG Ops, Inc., which then merged with SDG Ops LLC, authoritative guidance (ASC 805-50-30) required pushdown accounting to be applied for the Second Merger amongst entities under common control. As a result of the application of pushdown accounting, the separately issued financial statements of GRAIL reflect Illumina’s basis in the assets and liabilities of GRAIL which were remeasured to fair value as of the closing date of Illumina’s acquisition of GRAIL (“Closing Date”). Intangible assets included developed technology, in-process research and development, and trade names, as well as goodwill. There were also various other purchase price adjustment entries made in connection with the Acquisition that impacted the GRAIL standalone financial statements. We have explained these fluctuations within the section titled “—Results of Operations” below.
We expect to incur additional costs as a separate public company. These additional costs are primarily related to certain supporting functions that may differ from and be higher than the costs historically incurred or allocated to us.
The additional costs we expect to incur as a separate public company are summarized as follows:
•Accounting and audit related costs, professional services, and new systems and software to support the accounting, financial reporting, and audits as a standalone public company;
•Professional service costs, for additional support to enhance our capabilities in areas such as investor relations, accounting, financial reporting, treasury, risk management, and equity administration, among others; and
•Corporate governance costs, including but not limited to board of directors compensation and expenses, insurance, legal and other professional services fees, annual report and proxy statement costs, SEC filing fees, transfer agent fees, and stock exchange listing fees.
In addition, we have entered into a supply and commercialization agreement with Illumina. Under the terms of the agreement, regardless of whether our products incorporate any Illumina technology, we have agreed to pay to Illumina a high single-digit royalty, subject to certain reductions, in perpetuity on net sales generated by our
products or revenues otherwise generated or received by us, subject to certain exceptions, in the field of oncology. Per the terms of the Separation and Distribution Agreement with Illumina, the royalty arrangement is suspended until the earlier of December 24, 2026 or any earlier GRAIL Change of Control, at which time the high-single digit royalty will become payable.
Certain factors could impact the nature and amount of these separate public company costs, including the finalization of our staffing and infrastructure needs.
Key Factors Affecting Performance
We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:
•FDA and other regulatory approval and reimbursement. Our performance will be impacted by the extent to which we can secure reimbursement and coverage for Galleri. Prior to broader coverage and reimbursement in the United States, we will continue our work with clinics and health systems to accelerate utilization, and with self-insured employers and health insurers to offer and cover Galleri. Galleri is currently available as a laboratory developed test (“LDT”) in the United States and we have established private reimbursement from a number of self-insured employers and health plans, but do not currently have broader coverage and reimbursement by government healthcare programs, such as Medicare. While Galleri has not been approved or cleared by the FDA, FDA approval is currently not required to market our test in the United States. We plan to pursue FDA approval to support broad access for Galleri in the United States. We plan to complete a PMA submission with the FDA in the first half of 2026. The timing of this submission is subject to various risks and other factors, including the completion of clinical studies and our ongoing discussions with the FDA. Obtaining PMA approval can take several years from the time an application is submitted, if at all. Moreover, the FDA requirements that will govern MCED tests, as well as the breadth and nature of data we must provide the FDA to support the proposed intended use, may be subject to change, and as such it is difficult to predict what information we will need to submit to obtain approval of a PMA from the FDA for a proposed intended use. We continue to work with the FDA regarding the data we must provide the FDA to support our PMA submission for the proposed intended use. We believe that FDA approval, if obtained, could unlock large commercial payors in the United States and we are supporting proposed legislation in the United States to enable coverage of FDA-approved MCED tests by Medicare. If we obtain FDA approval, we expect to pursue inclusion of Galleri in the USPSTF’s guideline recommendation, although such inclusion is not certain even with FDA approval. We believe such inclusion would further increase adoption and market acceptance of our tests. Over time, to the extent Galleri becomes more accessible in the United States, we may opt to reduce pricing in order to access a broader population base and accelerate adoption. In the United Kingdom, we are working with NHS England to complete our NHS-Galleri Trial. The NHS will evaluate the final results from the NHS-Galleri Trial, which are expected to be available in 2026, before determining whether to implement the Galleri test in the NHS. We believe our work with the NHS and data generated from our NHS-Galleri Trial could facilitate adoption in other single-payor systems around the world and support evidence of clinical utility worldwide.
•International expansion. A component of our long-term growth strategy is to expand our commercial reach internationally. We have expanded internationally into the United Kingdom through our partnership with NHS England, and we expect to launch Galleri in the United Kingdom subject to the results of our NHS-Galleri Trial. We continue to evaluate international expansion opportunities and expect to expand into additional select geographies over time, including through distributors.
•Continued development of the market for MCED testing. Multi-cancer early detection is a relatively novel technology and the market for MCED tests is evolving. We coined the term “multi-cancer early detection” and continue to drive MCED as a solution to one of healthcare’s most important challenges. Our performance depends on the extent to which key stakeholders, including current and potential commercial partners, payors and health systems, regulators, policy makers, academic and community medical centers, and key opinion leaders and advocates, understand and support MCED testing as an effective solution for cancer screening. We make significant efforts to educate these key stakeholders
regarding the benefits of MCED and the clinical and economic value of our products, which we believe will continue to drive awareness of MCED and expand the commercial opportunity for our products.
•Demand for our products and customer mix. A key factor to our future success is and will be our ability to increase demand for, and sales of, Galleri from new and existing customers. Our commercial strategy is focused on innovative value-oriented partnerships and targets health systems, employers, payors, and life insurance providers. As Galleri is not currently broadly reimbursed, our ability to drive demand from these customers is directly linked to our ability to demonstrate the clinical and economic value of our test through clinical validation and real-world experience. As of June 30, 2024, we have entered into over 140 commercial partnerships, including with leading healthcare systems, employers, payors, and life insurance providers, and have established a network of over 11,000 prescribers across the United States in a pre-reimbursement setting. We believe this commercial network represents a significant opportunity to drive further demand for Galleri. The mix of customers from which we generate revenue from period to period has an impact on our revenue and gross margin. Galleri test pricing is generally based on our list price or, for certain customers, such as larger, higher-volume customers, negotiated contractual rates. For certain customers, we also offer rebates or discounts from time to time. Revenue generated from customers with negotiated contractual rates, or with rebates or discounts, is generally lower margin as compared to revenue generated based on list pricing. In addition, we have entered into a number of biopharmaceutical research partnerships for our research-use-only (“RUO”) offering under our precision oncology portfolio. Large customers, such as healthcare systems, employers, and biopharmaceutical partners, generally begin using our products by initiating pilots involving a limited number of tests. We believe that our ability to convert these initial pilots into long-term customer relationships has the potential to drive substantial long-term revenue. We also expect to increase demand from new customers through our efforts to further develop the market for MCED testing.
•Investment in clinical studies and innovation to support our strategy and growth. A significant aspect of our business is our investment in research and development and the ongoing evidence generation supporting the clinical performance and utility of Galleri. In particular, we have invested heavily in clinical studies and designed and executed what we believe is the largest clinical program in genomic medicine to date. These studies include: NHS-Galleri, CCGA, SUMMIT, STRIVE, SYMPLIFY, PATHFINDER, PATHFINDER 2, REFLECTION and REACH/Galleri-Medicare. We have established and maintained a leading voice in conversations regarding the early detection of multiple cancer types in the peer-reviewed literature. We have published data from these studies in high-profile journals and have presented such data at renowned medical conferences. We believe these studies are critical to driving adoption of our tests, as well as favorable coverage decisions, and expect to continue investment in data generation. In addition, we have invested heavily in the development of our methylation platform and extensive technological infrastructure. We expect our research and development expenses to decrease over the next three years as, in conjunction with our portfolio review, we determined to decrease investment in product programs beyond Galleri. Additionally, some of our large clinical studies and development of our automated platform are expected to conclude over the next three years. We will continue to prioritize key objectives for Galleri, including completion of our registrational studies and our premarket approval application.
•Leverage our operational infrastructure. We have made significant investments to build a scalable infrastructure capable of meeting significant demand while satisfying applicable certification requirements. Our facilities are able to process a substantial number of tests annually and are CAP-accredited and CLIA-certified. In addition, we engineered custom technology infrastructure and cloud-based tools to enable scalable data collection and analysis capabilities. With this foundational infrastructure in place, we have been able to generate scale efficiencies as the volume of tests sold has increased. As demand for our products increases, we expect to further leverage the scale efficiencies of our infrastructure and platform technology, which we believe will positively impact margins over time. In the future, it is possible that we may invest significant amounts in infrastructure to support new products or existing products in new markets.
While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See the “Risk Factors” section of this Quarterly Report on Form 10-Q for more information.
Components of Results of Operations
Screening Revenue and Screening Revenue — Related Parties
We currently derive screening revenue through the sale of Galleri within the United States and primarily through primary care physicians, health systems, employers, payors, and life insurance providers. Galleri is not currently broadly reimbursed. The test price is based on the negotiated contractual rate with our contracted customers, otherwise our standard list price applies. We identify each sale of our test to our customer as a single performance obligation; therefore, revenue is recognized at the point of time when the test result report is delivered. For self-pay patients, we have concluded that an implied contract exists, however the transaction price for the implied contract represents variable consideration as there are situations in which we do not expect to collect the full invoiced amounts from self-pay patients due to price concessions. We utilize the expected value approach to estimate the transaction price and apply a constraint for such variable consideration, on a portfolio basis. We monitor the estimated amounts to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required.
Development Services Revenue
We also derive revenue through our development services, which consist of services we provide to biopharmaceutical and clinical customers including support of clinical studies, pilot testing, research, and therapy development. We evaluate the terms and conditions included within our development services contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. Revenue from pilot and research services performed is recognized as performance obligations are achieved. We recognize revenue from development service agreements to support clinical study and companion diagnostic device development and regulatory submissions for the developed product(s) using an input method based on costs incurred to measure progress toward the completion and satisfaction of performance obligations.
Cost of Screening Revenue (Exclusive of Amortization of Intangible Assets), Cost of Development Services Revenue, Cost of Screening Revenue — Related Parties, and Cost of Development Services Revenue — Related Parties
Cost of revenue represents expenses that are incurred to produce and sell our products and services. For screening revenue, these costs consist of direct materials, direct labor including salaries and wages, bonus, benefits and stock-based compensation, shipping, royalties, and allocations of overhead and equipment depreciation. For development services, these costs consist of direct materials and patient sample acquisition, direct labor including salaries and wages, bonus, benefits and stock-based compensation, royalties, and allocations of overhead and equipment depreciation. Cost of screening revenue — related parties and cost of development services revenue — related parties represent the costs of supplies purchased from related parties used in the generation of revenue from all customers.
Cost of Revenue — Amortization of Intangible Assets
As a result of the application of pushdown accounting, intangible assets recognized in our standalone financial statements relate to our own technology, and consist of developed technologies and in-process research and development that were measured at fair value upon the Acquisition. Our developed technology includes intangible assets related to Galleri, designed as a cancer screening test for asymptomatic individuals over 50 years of age, as well as our diagnostic aid for cancer (“DAC”) that is being designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. As part of our Restructuring Plan, we are reducing investment in the development of products beyond Galleri, including DAC. The cost of identifiable intangible assets with finite lives, such as developed technology assets, are amortized on a straight-line basis over the assets’ respective estimated useful lives of 18 years.
Research and Development and Research and Development — Related Parties
Research and development expenses include costs incurred to develop our technology (prior to establishing technological feasibility), collect clinical samples, and conduct clinical studies to develop and support our products. These costs consist of personnel costs, including salaries, benefits, and stock-based compensation expense associated with our research and development personnel, costs associated with setting up and conducting clinical studies at domestic and international sites, laboratory supplies, consulting costs, depreciation, and allocated overhead including facilities and information technology expenses, which we do not allocate by product. We expense both internal and external research and development costs in the periods in which they are incurred. Research and development — related parties expenses include only those costs incurred with related parties as further discussed in Note 6 — Related Party Transactions in Item 1. Financial Statements of this Quarterly Report on Form 10-Q. Nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities are deferred and recognized as expense in the period in which the related goods are delivered or services are performed. We expect our research and development expenses to decrease over the next three years as, in conjunction with our portfolio review, we determined to decrease investment in product programs beyond Galleri. Additionally, some of our large clinical studies and development of our automated platform are expected to conclude in this period.
Sales and Marketing
Sales and marketing expenses consist primarily of personnel costs, including salaries, benefits and stock- based compensation expense, consulting costs, allocated overhead including facilities and information technology expenses, and travel associated with our commercial organization. Also included are costs associated with advertising programs that consist of brand and product awareness activities and trade events and conferences. Sales and marketing expenses also includes amortization of the trade name intangible assets that was recognized upon the Acquisition, which has been recorded in our financial statements as a result of the application of pushdown accounting. The cost of identifiable intangible assets with finite lives, such as trade names, are amortized on a straight-line basis over the assets’ respective estimated useful lives of 9 years. We expect our sales and marketing expenses to decrease immediately following implementation of the Restructuring Plan and to continue to decrease as a percentage of revenue over the next three years and long term.
General and Administrative and General and Administrative — Related Parties
G&A expenses consist of personnel expenses, including salaries, benefits and stock-based compensation expense, for executive, finance and accounting, legal, human resources, business development, corporate communications, medical affairs and management information systems personnel. Also included are professional fees, legal costs, including patent and trademark-related expenses and educational activities. The related party amount represents allocated stock administration expenses from Illumina. We will incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, director and officer insurance premiums, investor relations activities, and other expenses related to administrative and professional services. We expect our G&A expenses to decrease following implementation of the Restructuring Plan and to decrease as a percentage of revenue over the next three years and long term.
Goodwill Impairment
Upon the Acquisition, excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, was recognized by Illumina as goodwill. As a result of the application of pushdown accounting, the separately issued financial statements of GRAIL reflect the goodwill recorded by Illumina upon the Acquisition.
We eva